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ABSTRACT 
 
 
Estrogens have an essential role in the regulation of bone maturation in both sexes. 
Without the action of estrogens, growth plates remain open, allowing growth to 
continue even in adulthood. Some boys with constitutional delay of puberty (CDP) are 
unable to fully exploit their genetic growth potential. This prospective, randomized, 
placebo-controlled study was undertaken to evaluate whether suppression of estrogen 
synthesis in boys with CDP delays bone maturation and ultimately results in increased 
adult height.  
A total of 23 boys with CDP received a conventional, low-dose testosterone 
treatment for 6 months to induce the progression of puberty. Eleven of these boys were 
randomized to receive a specific and potent P450 aromatase inhibitor, letrozole, for one 
year, to suppress estrogen production, and 12 boys were randomized to receive placebo 
for one year. Another 10 boys received no treatment, thus serving as the untreated 
group.  
Letrozole was well tolerated, and no side-effects sufficient to indicate 
discontinuation of the treatment were observed. Letrozole inhibited estrogen synthesis 
effectively. During treatment with testosterone and letrozole 17β-estradiol 
concentrations remained at the pretreatment level, while they increased during treatment 
with testosterone alone as well as during spontaneous progression of puberty. 
Testosterone concentrations increased in all groups, but during letrozole treatment the 
increase was more than 5-fold higher than in the group treated with testosterone alone. 
Letrozole treatment delayed bone maturation. During the 18-month follow-up bone age 
advanced 0.9 year in the group treated with testosterone and letrozole and 1.7 years in 
the group treated with testosterone alone. From start to 18 months, an increase of 5.1 cm 
in predicted adult height was seen in the boys receiving testosterone and letrozole, while 
no change was seen in those receiving testosterone alone or in the untreated boys. This 
finding suggests that adult height can be increased in growing adolescents by 
suppressing estrogen synthesis. Furthermore, the boys with CDP may achieve an adult 
height closer to their genetic growth potential if estrogen actions are inhibited. 
No differences were present in changes in bone mineral content, bone mineral 
density (BMD), or bone mineral apparent density (BMAD), an estimate of true 
volumetric BMD, between the two treated groups, suggesting that a one-year treatment 
with letrozole is unlikely to have any major harmful effects on developing peak bone 
mass in pubertal boys. However, although lumbar spine BMAD increased in both 
treated groups, in the group treated with testosterone and letrozole, the increase was 
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statistically significant only 6 months after discontinuation of letrozole treatment. Thus, 
close follow-up of BMD during treatment with P450 aromatase inhibitors is warranted.  
The HDL-cholesterol concentration decreased in the group treated with 
testosterone and letrozole, whereas no change was observed in the group treated with 
testosterone alone. However, 6 months after the discontinuation of all treatments, the 
HDL-cholesterol concentrations were similar in all groups. The concentrations of LDL-
cholesterol or triglycerides did not change in any of the groups. Treatment with P450 
aromatase inhibitors may have disadvantageous effects on HDL-cholesterol, and 
therefore, follow-up of the lipid profile is important.  
Insulin concentrations decreased during letrozole treatment, while no change was 
observed during treatment with testosterone alone. Thus, inhibition of estrogen 
synthesis in early and midpubertal boys does not appear to diminish insulin sensitivity. 
As the boys on letrozole treatment had a higher increase in androgen concentrations, the 
finding further suggests that rising androgen concentrations during puberty do not 
directly contribute to the development of puberty-associated insulin resistance in boys.  
This study also clarified the role of endogenous estrogens in the regulation of 
gonadotropin secretion. We demonstrated that low physiological concentrations of 
endogenous estrogens inhibit LH and FSH secretion in boys during early and 
midpuberty. Moreover, during this stage of puberty the endogenous estrogen-mediated 
inhibition of LH secretion appears to occur at the site of the pituitary.   
In conclusion, P450 aromatase inhibitor treatment in boys with delayed puberty 
delays bone maturation and increases predicted adult height. This suggests that adult 
height can be increased in growing adolescents by suppressing estrogen synthesis. 
Future studies are needed to establish whether fourth-generation P450 aromatase 
inhibitors can effectively treat various growth disorders.  
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INTRODUCTION 
 
 
Increasing sex steroid secretion during puberty induces acceleration of growth and 
development of secondary sexual characteristics. Androgens in boys and estrogens in 
girls have been generally assumed to be the primary sex steroids causing the physical 
changes during puberty. 
 In 1994, the description of the estrogen receptor (ER) α-negative male 
revolutionized the traditional concept of the roles of sex steroids in the male (Smith et 
al. 1994). This 28-year-old man was 204 cm tall, had open epiphyses of long bones and 
consequently was still growing. He had no recollection of accelerated pubertal growth 
despite otherwise normal pubertal virilization. Soon thereafter, two males with similar 
phenotypes were described (Morishima et al. 1995; Carani et al. 1997). In these men, 
the effects of estrogens were suppressed due to mutations in the gene coding the P450 
aromatase enzyme which converts androgens to estrogens. Estrogen administration in 
these men closed the epiphyses and discontinued growth (Carani et al. 1997; Bilezikian 
et al. 1998). In all of these men, concentrations of androgens were normal or above 
normal. These case reports confirm that estrogens are essential for epiphyseal closure in 
males. Moreover, the reports suggest that estrogens induce pubertal growth acceleration 
but do not participate significantly in the regulation of linear prepubertal growth, since 
in the absence of estrogen action, growth progresses with a steady velocity.    
Delayed puberty is defined as a lack of initial signs of puberty by an age that is 
more than 2 standard deviation (SD) above the mean for the population. In most 
instances, the delay in pubertal development is not due to any underlying illness. 
Therefore, it can be regarded as an extreme end of the normal spectrum of pubertal 
timing and is defined as constitutional delay of puberty (CDP). However, some boys 
with CDP do not fully exploit their genetic growth potential, i.e., they remain shorter as 
adults than predicted from their parents’ heights (Crowne et al. 1990; LaFranchi et al. 
1991; Albanese et al. 1993, 1995). The delay in puberty and growth can result in 
considerable psychological distress for an adolescent, and in these situations, medical 
intervention is justified. These boys have been treated with androgens or anabolic 
steroids to induce development of secondary sexual characteristics and growth 
acceleration (Martin et al. 1986; Richman et al. 1988; Kaplowitz 1989; Albanese et al. 
1994). However, these treatments do not increase adult height (Blethen et al. 1984; 
Martin et al. 1986; Albanese et al. 1993).    
The role of estrogens in the regulation of bone maturation is unequivocal. The 
purpose of this study was explore whether inhibition of estrogen synthesis in boys with 
CDP delays maturation of growth plates and ultimately results in increased adult height. 
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This treatment may provide a means to help these boys achieve an adult height closer to 
their genetic growth potential.  
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REVIEW OF THE LITERATURE 
 
 
MALE PUBERTY 
 
Hypothalamic-pituitary-testicular axis 
 
Hypothalamus and pituitary 
 
The hypothalamic-pituitary-testicular axis is already operative in the prenatal period. 
High circulating gonadotropin concentrations at midgestation decrease before birth. 
During the first months of life the hypothalamic-pituitary-testicular axis is reactivated; 
the concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), 
sex steroids, and inhibin B are higher than in older prepubertal children (Forest et al. 
1974; Waldhauser et al. 1981; Andersson et al. 1998; Byrd et al. 1998; Bergadá et al. 
1999). The concentrations decrease early and remain relatively low in prepubertal years 
(Forest et al. 1974; Wu et al. 1989; Dunkel et al. 1990a, 1992; Wu et al. 1991, 1996; 
Byrd et al. 1998; Bergadá et al. 1999).  
The increase of gonadotropin-releasing hormone (GnRH) secretion in the 
hypothalamus, and consequently, gonadotropin secretion in the pituitary marks the 
onset of puberty. The current view is that the onset of puberty results from the removal 
of a central mechanism that inhibits GnRH secretion in prepuberty (Plant 2001). 
Augmentation of gonadotropin secretion first occurs at night (synchronized with sleep), 
leading to the clear night-day difference in gonadotropin concentrations (Boyar et al. 
1972, 1974; Parker et al. 1975; Dunkel et al. 1990a, 1992; Oerter et al. 1990; Wu et al. 
1991, 1996). With advancing puberty, daytime secretion also increases, with 
disappearance of the day-night difference at late puberty (Boyar et al. 1972, 1974; 
Parker et al. 1975; Oerter et al. 1990; Wu et al. 1996). GnRH and gonadotropins are 
secreted episodically (Waldhauser et al. 1981; Dunkel et al. 1990a, 1992; Wu et al. 
1991, 1996). The increase in LH and FSH concentrations during puberty is mainly due 
to an increase in gonadotropin pulse amplitude with a smaller increase in pulse 
frequency (Wu et al. 1996).  
The role of LH in the testes is to stimulate Leydig cells to secrete sex steroids, 
mainly testosterone. FSH controls the function of Sertoli cells, including secretion of 
inhibin B, and regulates spermatogenesis. During puberty sex steroid concentrations 
gradually increase, reaching the adult range at late puberty (Manasco et al. 1995; Klein 
et al. 1996; Byrd et al. 1998; Mitamura et al. 1999). Sex steroid concentrations are 
higher during sleep, and peak concentrations occur in the morning (Boyar et al. 1974; 
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Parker et al. 1975; Veldhuis et al. 1984; Mitamura et al. 1999). Inhibin B concentration 
increases at early puberty (Andersson et al. 1997; Byrd et al. 1998; Raivio et al. 1998; 
Crofton et al. 2002), reaching an adult male level at pubertal stage II (Andersson et al. 
1997). 
The testicular hormones also participate in the control of gonadotropin secretion 
by a feedback mechanism at the hypothalamus and the pituitary gland. In girls with 
primary gonadal failure, LH and FSH concentrations are above normal during infancy, 
normal or near-normal during childhood, and supranormal after the age of the onset of 
puberty (Conte et al. 1975). In prepubertal boys with primary testicular failure, FSH 
concentrations are above normal, but LH concentrations usually remain within normal 
range (Dunkel et al. 1990b). These findings suggest that testicular hormones are 
involved in negative feedback regulation of gonadotropin secretion during infancy 
(Conte et al. 1975). In childhood, testicular hormones have a role at least in the 
regulation of FSH concentrations (Dunkel et al. 1990b), although gonadotropin 
secretion is primarily under the control of the central nervous system (Plant 2001). After 
the onset of puberty, testicular hormones negatively regulate gonadotropin secretion 
(Conte et al. 1975). During puberty the mechanism of sex steroid-mediated inhibition 
changes. In early and midpubertal boys, testosterone infusion decreases LH 
concentrations and pulse frequency (Kletter et al. 1994), which is assumed to reflect the 
frequency of hypothalamic GnRH secretion pulses (Clarke et al. 1982; Levine et al. 
1982). However, it has no effect on LH pulse amplitude or GnRH-induced LH release 
(Kletter et al. 1994). These findings indicate that testosterone suppresses gonadotropin 
secretion primarily at the site of the hypothalamus in boys during early and midpuberty. 
In adult men, testosterone infusion decreases LH concentrations, LH pulse amplitude, 
and GnRH-induced LH release, but has no effect on LH pulse frequency, suggesting the 
pituitary as the primary site of negative feedback action of testosterone (Kletter et al. 
1992). Testosterone administration decreases gonadotropin concentrations both in 
normal men and in men with idiopathic hypogonadotropic hypogonadism whose 
pituitary-gonadal function has been normalized with long-term pulsatile GnRH 
replacement, but a greater decrease is observed in normal men (Finkelstein et al. 1991). 
This indicates both pituitary and hypothalamic effects of testosterone (Finkelstein et al. 
1991). Thus, sex steroids appear to inhibit gonadotropin secretion at the hypothalamus 
from early puberty onwards. The available evidence suggests that during puberty 
sensitivity of the pituitary gland to sex steroid-mediated negative feedback increases 
such that in adult men sex steroids inhibit gonadotropin secretion also at the site of the 
pituitary.  
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Testis  
  
Androgens  
Androgens are metabolized from cholesterol. The major potent circulating androgen in 
men is testosterone, which mostly circulates bound to plasma proteins, with 
approximately 2% occurring in free form (Dunn et al. 1981). More than 95% of 
testosterone is secreted from the testes (Riggs et al. 2002). Testosterone can be 
converted by the enzyme 5α-reductase to 5α-dihydrotestosterone (DHT), the majority of 
which is formed in extragonadal sites (Riggs et al. 2002; Figure 1). DHT is the main 
source of androgenic activity in many target tissues (Riggs et al. 2002). The adrenal 
cortex and the testis also secrete other androgens, mainly dehydroepiandrosterone 
(DHEA), DHEA sulfate (DHEA-S), and ∆4-androstenedione. These hormones have 
only weak androgenic activity, but they are important substrates for extragonadal 
synthesis of potent sex steroids (Riggs et al. 2002; Figure 1).  
 
 
 
 
 
 
 
Figure 1. Main pathways for extragonadal synthesis of sex steroids. Reversible (double 
arrows) and irreversible (single arrows) reactions are indicated. DHT, 
dihydrotestosterone; DHEA, dehydroepiandrosterone; S, sulfate. 
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Estrogens and P450 aromatase enzyme 
P450 aromatase is the key enzyme for estrogen biosynthesis. It catalyzes conversion of 
androgens to estrogens (Figure 1). P450 aromatase is encoded by a single gene, the 
CYP19, which is localized on chromosome 15q21.2. The same enzyme is expressed in 
many tissues, e.g. the testis, ovary, placenta, adipose tissue, bone, and brain (Simpson et 
al. 1994). Its expression is controlled by tissue-specific promoters regulated by different 
transcription factors (Simpson et al. 1994, 2001). Via P450 aromatase, testosterone is 
converted to estradiol, androstenedione to estrone, and DHEA to estriol. In males, the 
majority of estradiol and estrone are formed at extragonadal sites (MacDonald et al. 
1979). Although the circulating amounts of estrogens in males are relatively low, the 
local concentrations at those tissue sites where P450 aromatase is expressed are 
probably higher (Labrie et al. 1997, 1998; Simpson et al. 2001). Thus, local paracrine 
and intracrine actions of estrogens may have an important physiological role (Labrie et 
al. 1997, 1998).    
 
Inhibin B 
Inhibin B is a glycoprotein hormone, a dimer consisting of an α-subunit and a βB-
subunit. In males, it is produced mainly by the testis. Inhibin B has a physiological role 
in the feedback control of FSH secretion and is likely to be the most important feedback 
regulator of FSH secretion in adult males (Nachtigall et al. 1996; Anderson et al. 1997; 
Hayes et al. 2001). Concentrations of inhibin B and FSH correlate negatively from early 
to midpuberty onwards, suggesting that the negative feedback regulation loop maturates 
during puberty (Andersson et al. 1997; Byrd et al. 1998; Raivio et al. 2000).  
 
 
Normal physical development 
 
Rising concentrations of sex steroids during puberty induce development of secondary 
sexual characteristics and an increase in growth rate. The first sign of sexual maturation 
in boys is enlargement of testes and attainment of genitalia stage (G; according to 
Tanner) 2, which normally occurs between the ages of 9.5 and 13.5 years (Tanner 
1962). This is followed by a gradual increase in penile size and appearance of pubic 
hair. Axillary hair and the characteristic body odor appear, and voice pitch is lowered. 
An increase in height velocity starts after Tanner stage G 3, and the peak growth spurt 
(about 9.5 cm/year) occurs between stages G 3 and 5 (Tanner 1962; Tanner et al. 1966). 
The pubertal growth spurt lasts approximately 2 years, after which growth rate abruptly 
decelerates and eventually stops with the closure of epiphyseal growth plates (Tanner et 
al. 1966, 1985). The apex of increase in muscle mass is a late event occurring after the 
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peak growth spurt (Tanner 1962). Chest and facial hair appear at late puberty. 
Spermarche, the onset of the release of spermatozoa, usually occurs during the early 
stages of puberty, but considerable variation in pubertal characteristics is present at that 
time (Nielsen et al. 1986). 
In addition to wide variation at the age of onset of puberty, the time spent at any 
given stage of puberty and the order of appearance of different events also varies 
(Marshall et al. 1970; Nielsen et al. 1986). Boys normally progress from Tanner stage G 
2 to 5 in about 3 years, although some boys take longer than 5 years (Marshall et al. 
1970).  
 
 
Constitutional delay of puberty 
 
About 2.5% of children are delayed in developing secondary sexual characteristics. In 
most cases, there is no underlying pathology, and the condition represents an extreme 
end of the normal spectrum of pubertal timing. This developmental pattern is defined as 
constitutional delay of puberty (CDP) or constitutional delay of growth and 
puberty/maturation/development. CDP tends to be familial, although not all of the boys 
have positive family histories (Sedlmeyer et al. 2002). Characteristic for CDP is that 
stature is short for chronological age but appropriate for bone age and stage of pubertal 
development. Bone age is typically delayed to the same extent as puberty. Once puberty 
begins, it advances at normal rates. However, if puberty is much delayed, both peak 
height velocity and duration of growth spurt are smaller, and consequently, the total 
pubertal height gain is reduced. During late prepuberty and early puberty most of the 
height gain takes place in the extremities, and during the pubertal growth spurt in the 
spine. Thus, some individuals with CDP may end up with body disproportion at final 
adult height, i.e., a short spine in relation to leg length (Crowne et al. 1990; Albanese et 
al. 1993, 1995). Many studies also suggest that some boys with CDP do not exploit their 
full genetic growth potential (Crowne et al. 1990; LaFranchi et al. 1991; Albanese et al. 
1993, 1995). Furthermore, men with a history of CDP have been observed to have 
osteopenia in adult life (Finkelstein et al. 1992, 1996, 1999), but volumetric bone 
mineral density (BMD) has also been demonstrated to be normal in these men 
(Bertelloni et al. 1998a).  
Boys with CDP are smaller in height and in muscle mass and far less developed in 
secondary sexual characteristics compared with their age-matched peers. The delay in 
puberty and growth can lead to considerable psychological distress, and in these 
situations, medical intervention is justified. These boys have been treated with low-dose 
androgens or anabolic steroids to induce an increase in growth velocity and 
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development of secondary sexual characteristics (Martin et al. 1986; Richman et al. 
1988; Kaplowitz 1989; Albanese et al. 1994). Although capable of accelerating growth 
velocity, these treatments do not increase adult height (Blethen et al. 1984; Martin et al. 
1986; Albanese et al. 1993).   
 
 
 
SPECIFIC ROLES OF ANDROGENS AND ESTROGENS IN 
MALES 
 
Growth 
 
Growth velocity decreases during early childhood from the rapid rate of the first months 
of life, reaching a nadir (about 5 cm/year) just at the onset of puberty or in the early 
stages of puberty (Tanner et al. 1966, 1985). Growth velocity accelerates again at 
midpuberty, after the genital stage G 3 (at the age of 10.5 to 16 years), and reaches the 
highest value, about 9.5 cm/year, during mid- to late puberty, between the Tanner stages 
of G 3 and 5 (Tanner 1962; Tanner et al. 1966). Growth then decelerates and, at about 
the age of 18 years, stops with the closure of the epiphyses (Tanner et al. 1966, 1985).  
Growth is influenced by multiple regulators, including genetic, hormonal (e.g. 
growth hormone (GH), estrogens, androgens, thyroid hormones, glucocorticoids, 
insulin), and environmental (e.g. nutrition, emotional and physical well-being) factors.  
 
Androgens 
Testosterone has clearly been shown to stimulate growth. Testosterone concentrations 
correlated positively with growth velocity in adolescent boys (Merimee et al. 1991; 
Adan et al. 1994), testosterone infusion stimulated ulnar growth in pre- and early 
pubertal boys (Cassorla et al. 1984), and testosterone treatment in boys with CDP 
accelerated growth (Richman et al. 1988; Kaplowitz 1989; Albanese et al. 1994; 
Crowne et al. 1995). Since testosterone is able to be aromatized to estradiol or reduced 
to DHT, its growth-promoting effects may be androgen- or estrogen-mediated. An 
androgen-mediated mechanism is suggested by the finding that a nonaromatizable 
androgen, DHT, induced ulnar growth in pre- and early pubertal boys (Cassorla et al. 
1984). Although exogenous androgens stimulate growth in boys, endogenous androgens 
do not appear to have a very important role in regulation of the pubertal growth spurt, 
since in patients with complete androgen insensitivity syndrome (genetic males, 
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karyotype 46XY) with intact gonads, pubertal growth velocity is similar to that in 
normal females, albeit lower than in normal males (Zachmann et al. 1986). 
Androgen receptors have been localized in human growth plate chondrocytes 
(Abu et al. 1997), suggesting that androgens may stimulate growth by a direct local 
effect. It is unclear whether androgens have an influence on GH secretion. In one study, 
a nonaromatizable anabolic steroid, oxandrolone, increased GH secretion in pre- and 
early pubertal boys (Ulloa-Aguirre et al. 1990), but in another study, GH and insulin-
like growth factor I (IGF-I) concentrations did not change during oxandrolone treatment 
(Link et al. 1986). Moreover, DHT, a nonaromatizable androgen, decreased (Keenan et 
al. 1993) or did not change (Eakman et al. 1996) GH concentration in pre- and early 
pubertal boys, which suggests that growth stimulating effects of androgens are not 
mediated through the GH-IGF-I system.  
 
Estrogens 
A low-dose estradiol infusion accelerated ulnar growth in pre- and early pubertal boys, 
but higher doses had no effect on ulnar growth (Caruso-Nicoletti et al. 1985). In boys 
with familial male-limited precocious puberty, an aromatase inhibitor, testolactone, 
decreased growth velocity to near- normal prepubertal values, while an antiandrogen, 
spironolactone, alone did not decrease growth velocity significantly until testolactone 
was added (Laue et al. 1989). This suggests that estrogens are more important than 
androgens in pubertal growth acceleration in boys (Laue et al. 1989). The essential role 
of estrogens in the regulation of male growth was confirmed when a man with an 
inactivating mutation in the ERα gene was described (Smith et al. 1994). This 28-year-
old man was 204 cm tall (Smith et al. 1994). He had a bone age of 15 years, thus, the 
epiphyses of long bones were open and he was still growing (Smith et al. 1994). He had 
no recollection of pubertal growth acceleration (Smith et al. 1994). Soon thereafter, two 
other adult males with suppression of estrogen action due to mutations in the gene 
coding the P450 aromatase enzyme were described (Morishima et al. 1995; Carani et al. 
1997). At the time of diagnosis, these individuals were tall, had markedly delayed bone 
ages, and were still growing (Morishima et al. 1995; Carani et al. 1997). In these two 
aromatase-deficient men, estrogen administration closed the epiphyses and discontinued 
growth (Carani et al. 1997; Bilezikian et al. 1998). In all of these men, androgen 
concentrations were normal or above normal (Smith et al. 1994; Morishima et al. 1995; 
Carani et al. 1997; Bilezikian et al. 1998). These unique case reports suggest that 
endogenous estrogens are needed to induce the male pubertal growth spurt, but linear 
growth occurs without the action of estrogens. Furthermore, they clearly prove that 
estrogen action is needed for the closure of epiphyses and cessation of growth. A 
longitudinal follow-up of growth velocity and hormonal parameters in boys during 
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puberty provided further information about the role of estrogens in regulation of male 
pubertal growth (Klein et al. 1996). The first significant increase in estrogen 
concentration, determined by an ultrasensitive bioassay, occurred simultaneously with 
the peak growth velocity (Klein et al. 1996). However, at the time of the highest growth 
velocity, estrogen concentrations were still relatively low (Klein et al. 1996). Estrogen 
concentrations correlated positively with growth velocity before the peak growth spurt 
and negatively thereafter (Klein et al. 1996). All of these findings are concordant with 
the concept that the effect of estrogens on epiphyseal growth is biphasic (Figure 2). Low 
levels of estrogens, typical for early and midpubertal boys, stimulate growth, and higher 
levels, typical for late pubertal males, do not appear to be optimal for growth but instead 
accelerate epiphyseal fusion. 
ERα and ERβ have been localized in growth plate chondrocytes in humans, 
suggesting that estrogens are able to act directly at the epiphyseal growth plate (Kusec 
et al. 1998; Nilsson et al. 1999; Egerbacher et al. 2002). ER blockade with tamoxifen 
decreased GH secretion and IGF-I concentrations in late pubertal boys, indicating a 
stimulating effect of endogenous estrogens on GH secretion (Metzger et al. 1994). 
Although low-dose estrogen administration has been shown to increase GH production 
rate (Mauras et al. 1990), high-dose estrogen decreases IGF-I concentrations (Copeland 
1988). Thus, the biphasic effect of estrogens on growth can also partly be mediated 
through the GH-IGF-I system (Figure 2).  
 
 
 
Figure 2. Suggested model of the effects of estrogen in epiphyseal growth plate. GH, 
growth hormone; IGF-I, insulin-like growth factor I; +, enhancing effect; –, suppressing 
effect. 
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Bone mineral density and bone turnover 
 
Bone mass increases throughout childhood, with the maximum increment rate occurring 
during puberty, when bone mass doubles (Gilsanz et al. 1988; Bonjour et al. 1991; 
Kröger et al. 1993; Faulkner et al. 1996). The increase in bone mass results chiefly from 
growth in bone size; an increase in volumetric BMD has a smaller impact (Kröger et al. 
1992, 1993; Faulkner et al. 1996). Bone size increases by growth in length and by 
modeling, i.e., growth in thickness. Bone elongation ends with the closure of epiphyses 
around the age of 18 years in boys (Tanner et al. 1966, 1985), and bone modeling ends 
around the age of 20 years, approximately when peak bone mass is reached (Bonjour et 
al. 1991; Kröger et al. 1993; Välimäki et al. 1994). Simultaneously with bone growth, 
old bone is continuously replaced by new bone. This coupled process of bone resorption 
and formation is called remodeling. Thus, during growth the rate of bone turnover is 
affected by three different biological processes, i.e., longitudinal growth, modeling, and 
remodeling.  
Sex steroids have an important role in bone growth and in the development of 
peak bone mass. Hypogonadism has deleterious effects on peak bone mass (Finkelstein 
et al. 1987). Furthermore, sex steroids are responsible for sexual dimorphism of the 
skeleton, i.e. larger bones with larger diameter and greater cortical thickness in men 
than in women (Vanderschueren et al. 1998).  
 
Androgens 
Patients with androgen insensitivity syndrome have decreased BMD, even before the 
age when peak bone mass is reached (Bertelloni et al. 1998b; Marcus et al. 2000). This 
indicates that androgens have an essential role in the development of peak bone mass. 
The important role of androgens in bone mass accretion is further supported by men 
having larger bones with a thicker cortex than women. Indeed, in male rats, periosteal 
bone formation was stimulated by testosterone and DHT (Turner et al. 1990). 
Testosterone was also associated positively, and independently of estrogen, with BMD 
in adult men (Khosla et al. 1998; Center et al. 1999; van den Beld et al. 2000).  
The mechanism underlying regulation of bone metabolism by sex steroids was 
investigated in a study in elderly men whose gonadotropin secretion was suppressed by 
a GnRH agonist and conversion of androgens to estrogens was blocked by a P450 
aromatase inhibitor and simultaneously estradiol alone, testosterone alone, both, or 
neither were administered (Falahati-Nini et al. 2000). During different interventions 
serum concentrations of bone turnover markers were determined, with results indicating 
that testosterone, probably via an androgen-mediated mechanism, maintains bone 
formation, while its role in bone resorption is smaller (Falahati-Nini et al. 2000).  
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Estrogens 
The young adult men who cannot respond to or produce estrogens due to a defective 
ERα or P450 aromatase enzyme had significantly reduced BMD despite normal or 
supranormal androgen concentrations; estrogen administration improved BMD in the 
men with aromatase deficiency, whereas testosterone was ineffective (Smith et al. 1994; 
Morishima et al. 1995; Carani et al. 1997; Bilezikian et al. 1998). These case reports 
confirm the essential role of estrogens in the regulation of peak bone mass development 
in males. The correlation of bioavailable estradiol concentrations with BMD of the arms 
in pre- and early pubertal boys (Klein et al. 1998), and the relationship between an ER 
gene polymorphism and BMD in late pubertal boys (Lorentzon et al. 1999) are in 
accord with the concept of an important role for estrogens in bone mass accretion during 
growth and maturation in boys. The rate of increase in BMD of the arms in young men 
correlated positively with the concentrations of estrogen but not with those of 
testosterone (Khosla et al. 2001), which suggests that estrogens are more important than 
androgens in peak bone mass accretion in males. After attainment of peak bone mass, 
estrogen appears to be the dominant sex steroid for maintaining bone mass. Estrogen 
concentration, rather than that of testosterone, related positively with BMD in 
multivariate analysis in adult men (Slemenda et al. 1997; Khosla et al. 1998; 
Ongphiphadhanakul et al. 1998; Szulc et al. 2001), and in elderly men, the rate of bone 
loss associated better with the concentrations of bioavailable estradiol than with those of 
testosterone (Khosla et al. 2001).  
Estrogens appear to regulate bone turnover by decreasing bone resorption and 
increasing bone formation which was demonstrated in the above-mentioned direct 
interventional study, in which gonadotropin secretion and activity of P450 aromatase 
enzyme were suppressed before the administration of estradiol alone, testosterone alone, 
both, or neither in elderly men (Falahati-Nini et al. 2000). Furthermore, suppression of 
estrogen synthesis by a P450 aromatase inhibitor, anastrozole, in elderly men was 
accompanied by an increase in bone resorption marker and a decrease in bone formation 
markers (Taxel et al. 2001).  
 
 
Serum lipid concentrations  
 
Serum lipid concentrations change during adolescence simultaneously with the changes 
in body composition and the concentrations of several hormones. In boys, high-density 
lipoprotein (HDL) cholesterol concentration decreases and concentration of 
triglycerides increases (Morrison et al. 1978, 1979; Laskarzewski et al. 1983a; Viikari et 
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al. 1985; Porkka et al. 1994). An increase in low-density lipoprotein (LDL) cholesterol 
concentration appears to occur at late puberty (Morrison et al. 1979). Sex hormones are 
suggested to have a role in the regulation of lipid concentrations during puberty since 
sex differences in lipid profiles develop during adolescence, leading to a more 
atherogenic lipid profile in men than in women (Heiss et al. 1980).  
 
Androgens 
In adult men under physiological conditions, androgens do not appear to have 
disadvantageous effects on lipid concentrations. Higher HDL-cholesterol concentrations 
have been found to be associated with increased testosterone (Gutai et al. 1981; Heller 
et al. 1983; Dai et al. 1984; Lichtenstein et al. 1987; Haffner et al. 1993) or DHT 
(Hämäläinen et al. 1986) concentrations, after taking into account factors affecting lipid 
metabolism. No relationship between concentrations of LDL-cholesterol and 
testosterone (Heller et al. 1983; Dai et al. 1984; Haffner et al. 1993) or DHT 
(Hämäläinen et al. 1986) has been observed. Concentrations of triglycerides have been 
demonstrated to have no association (Heller et al. 1983; Dai et al. 1984) or an inverse 
association (Lichtenstein et al. 1987; Haffner et al. 1993) with testosterone 
concentrations.  
 The relationship between androgens and lipids in boys during puberty differs 
from that of adult males. In adolescent boys, higher testosterone concentrations were 
associated with lower HDL-cholesterol concentrations even when factors affecting lipid 
metabolism had been taken into account (Morrison et al. 1998, 2000). Moreover, 
testosterone (Kirkland et al. 1987; Arslanian et al. 1997) or DHT (Saad et al. 2001) 
treatment in boys with delayed puberty decreased HDL-cholesterol concentration. These 
findings suggest that HDL-cholesterol is regulated via an androgen-mediated 
mechanism in pubertal boys. Consequently, rising concentrations of androgens during 
puberty may induce a puberty-associated decrease in HDL-cholesterol. 
The role of androgens in the regulation of LDL-cholesterol in boys during puberty 
is unclear. In boys with delayed puberty, testosterone treatment was associated with a 
decreasing trend in LDL-cholesterol concentration, which did not, however, reach 
statistical significance (Arslanian et al. 1997), and DHT treatment had no effect on 
LDL-cholesterol concentration (Saad et al. 2001). An inverse relationship between 
testosterone and LDL-cholesterol concentrations was observed in one cross-sectional 
study (Morrison et al. 1998), but no association was found in another study (Morrison et 
al. 2000). Thus, androgens may not play as significant a role in the regulation of LDL-
cholesterol as in the regulation of HDL -cholesterol in adolescent boys.  
Androgens do not appear to significantly influence the regulation of triglycerides 
in boys during puberty. Testosterone and DHT treatment in boys with delayed puberty 
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had no impact on the concentrations of triglycerides (Arslanian et al. 1997; Saad et al. 
2001). Nor was there any association between concentrations of testosterone and 
triglycerides in adolescent boys (Morrison et al. 1998, 2000).  
In conclusion, the role of androgens in the puberty-associated changes in lipid 
concentrations remains somewhat unclear. While evidence suggests that in boys during 
puberty androgens contribute to the puberty-associated decrease in HDL-cholesterol 
concentrations, their role in the regulation of LDL-cholesterol and triglycerides may be 
less important.        
 
Estrogens 
Men with suppressed estrogen action due to mutations in P450 aromatase had an 
atherogenic lipid profile, i.e., subnormal HDL-cholesterol concentrations and elevated 
concentrations of LDL-cholesterol and triglycerides (Morishima et al. 1995; Carani et 
al. 1997). Estrogen administration in these men increased HDL-cholesterol 
concentration and decreased concentrations of LDL-cholesterol and triglycerides 
(Carani et al. 1997; Bilezikian et al. 1998). Low-dose estradiol administration in elderly 
men increased HDL-cholesterol concentration and decreased concentrations of LDL-
cholesterol and triglycerides (Giri et al. 1998). Thus, estrogens at physiological levels 
appear to affect lipid concentrations in adult males favourably. 
In adolescent boys, however, no relationship between estradiol and HDL-
cholesterol concentrations has been observed (Morrison et al. 1998, 2000). Estradiol 
concentrations were not associated with the concentrations of LDL-cholesterol or 
triglycerides in one study (Morrison et al. 1998), while an inverse relationship was 
shown in another study (Morrison et al. 2000). By contrast, changes in lipid 
concentrations during male adolescence have been shown to be explained to some 
extent by changes in estradiol concentration, as well as by changes in testosterone 
concentration and body mass (Laskarzewski et al. 1983a, 1983b). Evidence for the 
favorable effect of estrogens at physiological concentrations on lipids in adult males, 
and the contradictory results obtained in studies of adolescent boys may be related to 
the roles of sex steroids in the regulation of lipid metabolism varying in different age 
groups (Srinivasan et al. 1986).  
 
 
Insulin sensitivity 
 
During puberty insulin action is impaired and insulin secretion is increased in both 
sexes (Amiel et al. 1986, 1991; Bloch et al. 1987; Caprio et al. 1989; Smith et al. 1989); 
with the completion of pubertal development, insulin resistance subsides (Amiel et al. 
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1986; Caprio et al. 1989; Smith et al. 1989). The decrease in insulin sensitivity during 
puberty appears to be restricted to peripheral glucose metabolism, and compensatory 
hyperinsulinemia may thus facilitate protein anabolism during rapid growth by 
amplifying insulin’s effect on amino acid metabolism (Amiel et al. 1991; Heptulla et al. 
1997). Insulin sensitivity decreases during puberty simultaneously with rising 
concentrations of sex steroids (Goran et al. 2001). However, whether sex steroids 
regulate insulin sensitivity in males during puberty is unclear.  
A large body of evidence suggests that the decrease in insulin sensitivity during 
puberty is due to increasing action of GH. In studies including both sexes, insulin 
sensitivity correlated negatively with concentrations of GH (Amiel et al. 1986) and IGF-
I (Bloch et al. 1987; Caprio et al. 1989; Smith et al. 1989), and insulin sensitivity 
decreased and insulin secretion increased during GH treatment in children with short 
stature (Heptulla et al. 1997). However, relationships between GH and insulin 
sensitivity in studies including only boys have been contradictory. In one longitudinal 
study and in several cross-sectional studies of adolescent boys, insulin sensitivity, 
measured by an intravenous glucose tolerance test, was not associated with parameters 
reflecting GH secretion (Cook et al. 1993; Travers et al. 1995; Goran et al. 2001). 
Moreover, testosterone treatment of seven boys with delayed puberty did not alter 
insulin sensitivity, measured by the hyperinsulinemic-euglycemic clamp, despite an 
increase in IGF-I and mean nocturnal GH concentrations (Arslanian et al. 1997). 
However, in a recent study of 189 adolescent boys, IGF-I and IGF-binding protein 
(IGFBP) 3 concentrations were correlated strongly with insulin resistance, determined 
by the hyperinsulinemic-euglycemic clamp, suggesting that the GH-IGF-I system is an 
important contributor to insulin resistance during puberty in boys (Moran et al. 2002). 
 
Androgens 
In healthy adult males, suppression of testosterone secretion by a GnRH agonist and 
concomitant administration of different doses of testosterone leading to physiological 
testosterone concentrations (Singh et al. 2002) or administration of testosterone with 
supraphysiological doses (Hobbs et al. 1996) did not affect insulin sensitivity. 
Moreover, low concentrations of bioavailable testosterone failed to independently 
predict insulin resistance in normogonadal men (Abate et al. 2002). Existing data 
suggest that testosterone does not independently regulate insulin sensitivity in adult 
males. However, testosterone administration has been shown to improve insulin 
resistance in abdominally obese men simultaneously with a decrease of visceral fat mass 
(Mårin et al. 1992). The relationship between androgens and glucose-insulin 
homeostasis in men may, however, be explained to a large extent by concomitant 
alterations in fat tissue (Tchernof et al. 1995). Since plasma concentrations of free 
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testosterone are associated with total body fat and truncal and peripheral fat (Abate et al. 
2002), testosterone may have a role in the regulation of insulin sensitivity indirectly 
through its effect on fat tissue in adult males.     
Treatment of boys with delayed puberty with testosterone or a nonaromatizable 
androgen, DHT, did not change insulin sensitivity, suggesting that pubertal insulin 
resistance is not attributable to androgens (Arslanian et al. 1997; Saad et al. 2001). This 
conclusion is further supported by the findings of a longitudinal study in which changes 
in insulin sensitivity in boys during puberty were not associated with changes in 
testosterone concentrations (Goran et al. 2001). However, in a cross-sectional study, 
insulin sensitivity was predicted from testosterone concentration (Cook et al. 1993). 
Although further studies are needed to confirm whether endogenous androgens 
contribute to the development of puberty-associated insulin resistance in boys, existing 
evidence suggests that androgens do not have an essential role in the regulation of 
insulin sensitivity in boys during puberty. 
 
Estrogens 
Ethinyl estradiol administration to male-to-female transsexuals decreased insulin 
sensitivity (Polderman et al. 1994). By contrast, in a man with suppressed estrogen 
synthesis due to a mutation in the P450 aromatase gene, estrogen treatment decreased 
previously increased insulin concentration, suggesting an improvement of insulin 
sensitivity during estrogen administration (Morishima et al. 1995; Bilezikian et al. 
1998). The effect of estrogens on insulin sensitivity may be dose-dependent. The 
available data suggest that physiological concentrations of estrogens may be a 
prerequisite for normal insulin metabolism. 
Data concerning the role of estrogens in the regulation of insulin sensitivity in 
boys during puberty are very scarce. In a longitudinal study, changes in insulin 
sensitivity in boys during progression of puberty were not associated with changes in 
estradiol concentrations (Goran et al. 2001). However, since GH secretion is stimulated 
by estrogens (Metzger et al. 1994), estrogens may participate in the regulation of insulin 
sensitivity during puberty indirectly through the GH-IGF-I system.  
 
 
Regulation of hypothalamic-pituitary-testicular axis 
 
The reproductive system is maintained by the episodic secretion of GnRH from the 
hypothalamus. GnRH, via hypophyseal-portal blood, induces the release of LH and 
FSH from the pituitary gland. These stimulate the secretion of gonadal hormones which, 
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in turn, feed back to the hypothalamus and the pituitary gland, thus participating in the 
regulation of GnRH and gonadotropin secretion.  
 
Androgens 
Patients with complete androgen insensitivity syndrome have increased concentrations 
of LH, despite normal or high concentrations of estrogens and androgens, but usually 
have normal concentrations of FSH (Judd et al. 1972; Faiman et al. 1974; LaCroix et al. 
1979). These findings indicate that endogenous androgens inhibit LH secretion in adult 
males, while their role in the control of FSH secretion may be less important. 
Testosterone infusion decreased gonadotropin concentrations and LH pulse amplitude in 
men with idiopathic hypogonadotropic hypogonadism whose pituitary-gonadal function 
had been normalized with long-term pulsatile GnRH replacement, demonstrating that 
negative feedback of testosterone occurs at the pituitary (Finkelstein et al. 1991). 
Testosterone administration decreased gonadotropin concentrations to a greater extent 
in normal men than in those with idiopathic hypogonadotropic hypogonadism and 
decreased LH pulse frequency in normal men, indicating that the hypothalamus is 
another site of negative feedback action for testosterone (Finkelstein et al. 1991). 
However, effects of testosterone can be androgen- or estrogen-mediated. An infusion of 
a nonaromatizable androgen, DHT, at the blood production rate of testosterone 
decreased LH concentrations and LH pulse frequency but did not change LH pulse 
amplitude, which suggests that androgen-mediated negative feedback occurs primarily 
at the hypothalamus (Veldhuis et al. 1984). Actions of exogenously administered 
steroids may, however, differ from the effects of endogenous steroids. Inhibition of 
endogenous androgen-mediated effects by androgen receptor antagonist flutamide 
increased LH concentration, but exogenous GnRH-induced LH release did not change, 
suggesting that negative feedback of endogenous androgens also occurs primarily at the 
site of the hypothalamus (Urban et al. 1988; Veldhuis et al. 1992). Another androgen 
receptor blocker, Anandron®, increased basal and exogenous LH-releasing hormone-
stimulated LH concentrations and LH pulse frequency and amplitude (Gooren et al. 
1987). These findings also support endogenous androgens inhibiting gonadotropin 
secretion at the site of the hypothalamus, but do not exclude the possibility of negative 
feedback at the pituitary in adult males.   
In late pubertal boys, flutamide administration increased LH concentrations but 
did not change FSH concentrations, probably due to an increase in estradiol 
concentrations (Kerrigan et al. 1994). Endogenous androgen-mediated inhibition of LH 
secretion appears to occur primarily at the site of the hypothalamus in late pubertal boys 
since after inhibition of endogenous androgen action, LH concentrations and pulse 
frequency increased, but exogenous GnRH-induced LH release remained unchanged 
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(Kerrigan et al. 1994). Endogenous androgens seem to regulate gonadotropin secretion 
in males already during the early stages of puberty, as an antiandrogen, spironolactone, 
increased both LH and FSH concentrations in a group composed of pre-, early, and 
midpubertal boys (Santen et al. 1976). Moreover, nonaromatizable androgens or 
anabolic steroids (oxandrolone, DHT, and fluoxymesterone) decreased gonadotropin 
concentrations in pre- and early pubertal boys (Hopwood et al. 1979; Keenan et al. 
1993; Malhotra et al. 1993).  
In conclusion, endogenous androgens appear to inhibit gonadotropin secretion 
from the early stages of puberty onwards. During late puberty endogenous androgen-
mediated negative feedback occurs primarily at the site of the hypothalamus, and in 
adult males, also at the hypothalamus, but possibly at the pituitary as well.  
 
Estrogens 
The essential role of endogenous estrogens in the regulation of gonadotropin secretion 
in adult males was demonstrated with the three different case reports of impaired 
estrogen action, referred to above (Smith et al. 1994; Morishima et al. 1995; Carani et 
al. 1997; Bilezikian et al. 1998). In these reports, gonadotropin concentrations were 
elevated and decreased with estrogen therapy in the men with aromatase deficiency 
(Smith et al. 1994; Morishima et al. 1995; Carani et al. 1997; Bilezikian et al. 1998). 
Suppression of estradiol concentrations by the P450 aromatase inhibitor, anastrozole, 
increased LH and FSH concentrations in normal men and in those with idiopathic 
hypogonadotropic hypogonadism whose pituitary-gonadal system had been normalized 
by long-term pulsatile GnRH therapy (Hayes et al. 2000). Despite similar changes in 
sex steroid concentrations, the increase was greater in the normal men (Hayes et al. 
2000). This study proved that in adult males gonadotropin secretion is regulated by 
endogenous estrogens at both the pituitary and the hypothalamus. 
The role of low concentrations of endogenous estrogens in the regulation of 
gonadotropin secretion in boys during puberty has been unclear. In early and 
midpubertal boys, the hypothalamic-pituitary axis is responsive to estrogens since 
estradiol infusion decreases LH concentration (Kletter et al. 1997). When estradiol 
concentrations were increased in early and midpubertal boys to the adult male range by 
estradiol infusion, LH pulse frequency decreased, but neither LH pulse amplitude nor 
the exogenous GnRH-induced LH response changed, indicating that supraphysiological 
concentrations of circulating estrogens inhibit LH secretion at the site of the 
hypothalamus (Kletter et al. 1997).  
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AIMS OF THE STUDY 
 
 
The objectives of the study were: 
 
1. To investigate prospectively whether combining the P450 aromatase inhibitor, 
letrozole, which suppresses estrogen synthesis, with testosterone treatment in boys with 
CDP would delay bone maturation and increase adult height (I). 
 
2. To evaluate the role of sex steroids in boys during puberty in the regulation of 
− BMD and bone turnover (IV). 
− serum lipid concentrations (III). 
 − insulin sensitivity (III).  
− gonadotropin secretion (II). 
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PATIENTS AND METHODS 
 
 
ETHICAL CONSIDERATIONS 
 
The protocol was approved by the Ethics Committee of the Hospital for Children and 
Adolescents and the National Agency for Medicines. Informed written consent was 
obtained from the patients and their guardians. 
 
 
PATIENTS AND STUDY PROTOCOL 
 
The boys were referred to the Hospital for Children and Adolescents, University of 
Helsinki, for evaluation of delayed puberty and/or short stature. A total of 38 boys were 
seen at the outpatient clinic; three of these boys refused to enter the study and two were 
excluded because they had already reached midpuberty (Figure 3). Thus, 33 boys were 
recruited in all (Table 1). The diagnosis of constitutional delay of puberty was defined 
as a Tanner genital or pubic hair stage (P) observed at an older age than the mean +2 SD 
for healthy Finnish boys (Ojajärvi 1982) or a testis volume of less than 4 ml after 13.5 
years of age. At entry, none of the boys had had any pubertal increase in growth 
velocity. The boys whose target height would have been more than +1 SD would have 
been excluded from the study, but none of the boys fulfilled this criterion. Neither 
medical history, clinical examination, nor routine laboratory tests revealed any signs of 
chronic illnesses which could account for the delayed puberty. Twenty-five (76%) of 
the boys had a family history of delayed puberty. None had received any previous sex 
hormone treatment. Two boys were receiving inhaled corticosteroid treatment for 
asthma. 
Ten boys with a mean age of 15.0 ± 0.2 years (range, 14.4 to 16.8) decided to wait 
for spontaneous progression of puberty without medical intervention, and thus, 
composed the untreated group (Figure 3). Twenty-three boys with a mean age of 15.1 ± 
0.2 years (range, 13.5 to 16.1) desired medical intervention and were randomly assigned 
to receive one of two treatments (Figure 3). The boys in the testosterone-plus-placebo-
treated group (12 boys) received testosterone enanthate (Testoviron-Depot-250, 
Schering, Berlin, Germany) six times at a dose of 1 mg/kg intramuscularly every four 
weeks, and placebo orally once a day for 12 months (Figure 4). The testosterone-plus-
letrozole-treated group (11 boys) received testosterone enanthate (as above) as well as a 
specific and potent fourth-generation aromatase inhibitor, letrozole (Femar, Novartis 
AG, Stein, Switzerland, commercially purchased from a hospital pharmacy), 2.5 mg  
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Table 1. Clinical characteristics of the boys at the start of follow-up. 
_____________________________________________________________________ 
 No treatment Testosterone + Testosterone + 
  placebo letrozole 
_____________________________________________________________________ 
Chronological age (years)  15.0 ± 0.2 15.0 ± 0.2 15.2 ± 0.2 
Bone age (years) a 12.7 ± 0.3 12.6 ± 0.4 13.1 ± 0.2 
Height (cm) 154.3 ± 1.4 151.9 ± 2.4 155.3 ± 2.1 
Pubertal stage b G2(2-3) P2(1-2) G2(2-3) P1(1-2) G2(2-3) P1(1-2) 
Testis volume (ml) c 5.9 ± 0.9 6.9 ± 1.2 5.5 ± 0.6 
Predicted adult height (cm) d 178.3 ± 1.4 174.9 ± 2.4 176.5 ± 1.7 
_____________________________________________________________________ 
Mean ± SEM or median (range). a By the method of Greulich and Pyle (1959).  b According to Tanner 
(1962).  c From the formula length x width2 x 0.52 (Hansen et al. 1952). d By the Bayley-Pinneau (1952) 
method.   
 
 
orally once a day for 12 months (Figure 4). The project was conducted as a randomized, 
double-blind, placebo-controlled study between the treated groups (I, III, IV).  
The subjects were examined at the start and at 2 months (approximately 7 days 
after the 3rd testosterone injection), 5 months (approximately 7 days after the 6th 
testosterone injection), 12 months, and 18 months (Figure 4). Nine boys in the untreated 
group, 10 in the testosterone-plus-placebo-treated group, and 11 in the testosterone-
plus-letrozole-treated group completed the 2-month follow-up; 8, 11, and 11 boys, 
respectively, completed the 5-month follow-up; 8, 11, and 10, respectively, the 12-
month follow-up; and 7, 10, and 10, respectively, the 18-month follow-up (Figure 3). 
One boy in the testosterone-plus-letrozole-treated group was considered noncompliant 
and his results were excluded from analyses (Figure 3). Since nocturnal gonadotropin 
pulses had been determined in 5 testosterone-plus-placebo-treated boys and only 3 
testosterone-plus-letrozole-treated boys during the randomized, placebo-controlled 
study, 2 boys were subsequently treated with testosterone and letrozole, and were 
included in Study II (Figure 3). Both of these boys completed the 5-month follow-up 
(Figure 3).  
 
 
 
Figure 4. Treatment regimens and time points of follow-up.  
0 2 5 12 18 months
TESTOSTERONE 
PLACEBO / LETROZOLE 
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LETROZOLE, A P450 AROMATASE INHIBITOR 
 
Letrozole (CGS 20267) is a novel, specific, and potent fourth-generation nonsteroidal 
aromatase inhibitor which inhibits the conversion of testosterone to 17β-estradiol and of 
∆4androstenedione to estrone. It is mostly metabolized in the liver, and letrozole and its 
metabolites are excreted mainly via the kidneys. The plasma terminal elimination half-
life is approximately 2 days. Steady-state plasma concentrations are reached within 2 to 
6 weeks with a dose of 2.5 mg once a day. The current official indication for letrozole is 
breast cancer. Letrozole has been shown to be well tolerated, and it has no other 
pharmacological effects in vivo (Iveson et al. 1993; Trunet et al. 1993; Lipton et al. 
1995; Ingle et al. 1997; Dombernowsky et al. 1998; Gershanovich et al. 1998). 
Metabolic and hormonal effects of another fourth-generation aromatase inhibitor, 
anastrozole, in late pubertal boys and adult males (aged 14-22 years) have been studied 
previously (Mauras et al. 2000).  
 
 
METHODS 
 
Auxological measurements and staging in puberty (I) 
 
Heights were measured on a Harpenden stadiometer with 0.1 cm precision. Pubertal 
stages were assessed according to Tanner (1962). Testis volumes were calculated from 
the formula length x width2 x 0.52 (Hansen et al. 1952) and were presented as means of 
the two testes. 
 
 
Bone age (I) 
 
Bone ages were determined blindly by the method of Greulich and Pyle (1959). Bone 
age x-ray films of each time point were first ranked in successive order according to 
maturation, after which the bone age for each film was determined. 
 
 
Adult height prediction (I) 
 
Adult height predictions were calculated using the Bayley-Pinneau (1952) method; the 
table for boys with average skeletal maturity was used, as the bone ages in most of the 
boys exceeded the range of bone ages reported for boys with retarded skeletal maturity. 
The Bayley-Pinneau method employs tables giving the percentages of final height 
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acquired at each bone age, as estimated by the method of Greulich and Pyle. This 
method has been demonstrated to give accurate adult height predictions for Finnish 
boys with CDP (Lenko 1979).  
 
 
Body composition (III, IV) 
 
Weight was measured with underwear on. The body mass index (BMI) was calculated 
from the following formula: weight (kg) / height2 (m2). Fat-free mass (FFM), fat mass 
(FM), and percentage of FM was determined by bioelectrical impedance analysis. FFM 
was determined with an equation developed by Houtkooper et al. (1992). FM was 
determined by subtracting FFM from weight. The percentage of body fat was also 
estimated from the sum of six skinfolds (Anyan 1978) in most of the boys from 2 
months onwards. These percentages of body fat and the percentages of body fat 
measured by the bioelectrical impedance analyses correlated at each time point, 
validating the measurements obtained by bioelectrical impedance analysis. The changes 
in FFM and FM could be determined within 5 months in 9 boys treated with 
testosterone and placebo and in 10 boys treated with testosterone and letrozole, but 
within 12 months only in 6 and 9 boys, and within 18 months only in 6 and 7 boys, 
respectively.   
 
   
Bone mineral density measurement (I, IV) 
 
The bone mineral content (BMC) of the first through fourth lumbar spines and the 
femoral neck were determined by dual-energy x-ray absorptiometry (Hologic QDR-
1000, Hologic Inc., Waltham, MA, USA) at the start and at 5 months, 12 months, and 
18 months. The BMD was calculated by dividing the quantity of bone mineral within 
the scan area (BMC) by the projected area within the region of interest (area). 
According to the manufacturer, the coefficient of variation of BMD in the lumbar spine 
is 0.6% and in the femoral neck 1.5% in a normal population. The areal BMD obtained 
by this method can be confounded by changes in bone thickness. To minimize the 
contributions of bone dimensions, bone mineral apparent density (BMAD), an estimate 
of volumetric BMD, was also determined. Lumbar spine BMAD was calculated using 
the formula BMC ÷ (area)1.5, and femoral neck BMAD using the formula BMC ÷ 
((area)2 ÷ 1.6), corresponding to the length of the scanned area (1.6 cm) (Katzman et al. 
1991). 
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Laboratory methods 
 
All of the venous blood samples were drawn between 07:30 and 10:15, typically after a 
12-hour fast, but after at least a 10-hour fast. Serum concentrations of bone turnover 
markers, insulin, and inhibin B were determined at the start and at 5 months, 12 months, 
and 18 months; all other parameters were measured at every visit.  
 
17β-estradiol (I-IV)  
Serum 17β-estradiol concentrations were determined by a modified radio-immunoassay 
(RIA) using coated tube technology (Spectria estradiol, Orion Diagnostica, Espoo, 
Finland) after diethyl ether extraction (700 µl serum plus 5 ml diethyl ether) 
(Norjavaara et al. 1996). The detection limit of the assay was 6 pmol/l. The interassay 
coefficient of variation (CV) was 27% for concentrations of 8-15 pmol/l, and 17% for 
concentrations of 15-30 pmol/l. The intra-assay CV ranged from 12% to 16% for 
concentrations of 8-50 pmol/l. 
 
Testosterone and DHT (I-IV)  
Serum testosterone and DHT concentrations were measured by RIA after separation of 
steroid fractions on a Lipidex-5000 microcolumn (Packard-Becker, B.V. Chemical 
Operations, Groningen, The Netherlands) (Apter et al. 1976). The inter- and intra-assay 
CVs for testosterone were 15% at a concentration of 15.6 nmol/l. For DHT, the 
interassay CV was 17% and the intra-assay CV 14% at a concentration of 2.5 nmol/l. 
 
IGF-I and IGFBP-3 (I, III, IV) 
Serum IGF-I and IGFBP-3 concentrations, surrogate markers of GH secretion, have 
been shown to reflect GH secretion in healthy children (Blum et al. 1993). The 
concentrations of IGF-I and IGFBP-3 were determined by RIAs (DiaSorin, Stillwater, 
MN, USA, and Nichols Institute Diagnostics, San Juan Capistrano, CA, USA, 
respectively). For IGF-I, the interassay CV was 15.2% at a concentration of 32.7 nmol/l 
and the intra-assay CV 9.1% at a concentration of 24.8 nmol/l. The interassay CV for 
IGFBP-3 was 12% and the intra-assay CV 5.6% at a concentration of 4.1 mg/l. 
   
Bone turnover markers (IV) 
Measuring serum concentrations of bone turnover markers offers an indirect way to 
study various aspects of bone metabolism. Type I collagen degradation and bone 
resorption are mirrored by a degradation product, cross-linked carboxyterminal 
telopeptide of type I collagen, which was measured by two different methods (CTx and 
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ICTP) (Eriksen et al. 1993; Risteli et al. 1999). The rate of type I collagen synthesis, 
which accompanies bone formation, is reflected by the serum concentration of a 
synthesis by-product, carboxyterminal propeptide of type I procollagen (PICP) (Eriksen 
et al. 1993; Risteli et al. 1999). Bone formation was also estimated by measuring serum 
concentrations of osteocalcin (OC) (Brown et al. 1984) and alkaline phosphatase (ALP), 
the bone isoform of which constitutes about 75-90% of total serum ALP activity in 
children over the age of 4 years (Schönau et al. 1997).  
Serum CTx concentrations were measured by Serum CrossLaps ELISA (Nordic 
Bioscience Diagnostics, Herlev, Denmark). The interassay CV for CTx was 7.1% at a 
concentration of 4.2 nmol/l and the intra-assay CV 5.5% at a concentration of 5.6 
nmol/l. Serum ICTP and PICP concentrations were determined by RIA (Orion 
Diagnostica, Espoo, Finland). The interassay CV for ICTP was 8.0% at a concentration 
of 21.2 µg/l and the intra-assay CV 4.1% for concentrations of 10-100 µg/l. The 
interassay CV for PICP was 5.2% at a concentration of 191 µg/l and the intra-assay CV 
3.0% for concentrations of 50-400 µg/l. The serum OC concentrations were measured 
by an immunoradiometric assay (Nichols Institute Diagnostics, San Juan Capistrano, 
CA, USA). The interassay CV for OC was 4.4% and the intra-assay CV 3.6% at a 
concentration of 73 µg/l. Serum ALP concentrations were determined using a Hitachi 
917 Modular autoanalyzator. The interassay CV for ALP was 9.3% at a concentration of 
729 U/l. 
 
Lipids (III) 
Concentrations of serum total cholesterol, HDL-cholesterol, and triglycerides were 
determined by enzymatic colorimetric tests (Roche Diagnostics GmbH, Mannheim, 
Germany). The interassay CV for total cholesterol was 1.7% at a concentration of 5.5 
mmol/l and the intra-assay CV 0.8% at a concentration of 6.0 mmol/l. The inter- and 
intra-assay CVs for HDL-cholesterol were 2.6% and 1.3%, respectively, at a 
concentration of 0.6 mmol/l, and for triglycerides 1.8% (2.5 mmol/l) and 1.5% (2.3 
mmol/l), respectively. Serum LDL-cholesterol concentrations were calculated using the 
equation of Friedewald et al. (1972).  
 
Insulin (III) 
Serum insulin concentrations were determined by RIA (Pharmacia & Upjohn 
Diagnostics AB, Uppsala, Sweden). The intra-assay CV and total CV for insulin were 
8.0% at a concentration of 20.4 mU/l. 
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Gonadotropins (I, II) 
Serum LH and FSH concentrations were measured by ultra-sensitive 
immunofluorometric assay (Wallac, Turku, Finland) (Dunkel et al. 1990b). The 
sensitivity of the assay for LH and FSH was 0.05 IU/l, as defined by the mean +2 SD of 
20 (LH) or 96 (FSH) replicates of a zero sample. The interassay CV for LH ranged from 
3.2% to 4.6% at concentrations of 2.0-54.0 IU/l, and the interassay CV for FSH from 
2.6% to 3.3% at concentrations of 6.6-35.1 IU/l. The intra-assay CV was calculated by 
measuring 12 or 36 replicates at 3 different concentrations of LH and FSH. The intra-
assay CV for LH was 4.1% at a concentration of 0.35 IU/l (n=36), 2.0% at a 
concentration of 3.0 IU/l (n=36), and 1.6% at a concentration of 8.7 IU/l (n=12). The 
intra-assay CV for FSH was 4.4% (0.25 IU/l; n=36), 1.8% (2.9 IU/l; n=36), and 1.6% 
(6.7 IU/l; n=12). These results were used for calculating the assay SD coefficients for 
the pulse analysis program. LH concentrations of less than 0.1 IU/l were treated as 0.1 
IU/l. 
 
Inhibin B (I, II) 
Serum inhibin B concentrations were determined by enzyme-linked immunosorbent 
assay (Serotec, Oxford, UK). The interassay CV was less than 8% at concentrations of 
115 ng/l and 282 ng/l, and the intra-assay CV was less than 5% at concentrations of 115 
ng/l and 272 ng/l. 
 
 
GnRH test (II) 
 
At the start, at 5 months, and at 12 months, GnRH (Relefact®, 3.5 µg/kg, maximum 100 
µg; Hoechst Marion Roussel, Deutschland GmbH, Frankfurt, Germany) was 
administered intravenously, and LH concentrations were measured from samples 
obtained at 0 (before), 20, 30, and 60 minutes and FSH concentrations at 0 (before), 30, 
60, and 90 minutes after administration of GnRH in all boys. The GnRH tests were 
started between 07:30 and 10:15. The GnRH-induced gonadotropin response was 
defined as the difference between the basal and the GnRH-induced peak gonadotropin 
concentrations.  
 
 
Gonadotropin pulse analysis (II) 
 
Nocturnal gonadotropin pulses were studied at the start and at 5 months in 5 boys 
treated with testosterone and placebo and in 5 boys treated with testosterone and 
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letrozole. For determination of nocturnal gonadotropin pulses, an indwelling 
intravenous cannula was inserted approximately one hour before the beginning of 
sampling. Sleep was monitored visually by trained nursing personnel. The serum LH 
and FSH concentrations were determined every 15 minutes. One boy fell asleep at 
03:10, at the time point before the treatment, the other boys fell asleep before midnight.  
The serum LH and FSH concentrations from each individual at a given time point 
were analyzed in the same assay. LH and FSH pulsations were analyzed by a 
computerized pulse analysis program, Munro (Zaristow Software, East Lothian, 
Scotland). The program identifies secretory peaks by height and duration from a 
smoothed baseline, using the assay SD as a scale factor. Munro is an adaptation of the 
Pulsar Program developed by Merriam and Wachter (1982). The only essential 
difference is in the calculation of the baseline; in the Munro program, the baseline is 
generated by linear interpolation between the nadirs, followed by smoothing, using a 
moving average. The remaining stages of the Munro algorithm are identical with those 
of the Pulsar program. As the baseline in the Munro program is calculated from the 
nadirs rather than from the moving average of the data, this program can process data 
containing pulses of variable widths and amplitudes. This is considered essential in the 
analysis of FSH pulses, which are wider than LH pulses. The cut-off parameters G1-5 
of the Munro program for LH were set at 3.98, 2.4, 1.68, 1.24, and 0.93, and those for 
FSH were set at 10.0, 2.4, 1.68, 1.24, and 0.93 times the intra-assay SD as criteria for 
accepting peaks 1, 2, 3, 4, and 5 points wide, respectively. The smoothing time, a 
window used to calculate the moving average, was set at 135 minutes, i.e., 9 data points 
wide for both LH and FSH. With these settings, the program did not detect any peaks 
when 33 consecutive samples from plasma pools with LH concentrations of 
approximately 0.35 IU/l and 3.0 IU/l and with FSH concentrations of approximately 
0.25 IU/l and 2.9 IU/l were assayed. Thus, use of a special program for minimizing 
false-positive error in pulse detection (Veldhuis et al. 1985) was not deemed necessary. 
Missing values comprised approximately 0.6% of total samples and were left blank. The 
interpulse interval was defined as the time interval between consecutive peaks. 
 
 
Statistical analysis 
 
Values are expressed as means ± standard error of the mean (SEM) unless otherwise 
reported. Analyses were conducted with the SPSS statistical software for Windows, 
Release 8.0.2 (I, II, III) or Release 10.0.7 (IV) (SPSS, Inc., Chicago, IL, USA). One-
way analyses of variance, Student’s unpaired t-test, Kruskal-Wallis nonparametric 
analyses of variance, or Mann-Whitney U-test were used as appropriate in studying the 
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differences between groups at the start or at the time point of 18 months. Student’s 
paired t-test or the Wilcoxon matched pairs signed rank test were used for analyses of 
the changes within groups during the follow-up. For analysis of serial measurements, 
the summary measures, the differences from the start, were calculated for each subject, 
and these values were treated as raw data for the appropriate statistical analysis; 
Student’s unpaired t-test or Mann-Whitney U-test were used as appropriate. Pearson’s 
correlation coefficient was used to investigate the relationship between growth velocity 
and hormone concentrations (I). Pearson’s or Spearman’s correlations were used to 
assess the relationships between changes in insulin concentrations and changes in BMIs, 
concentrations of 17β-estradiol, testosterone, IGF-I, and IGFBP-3, and the relationships 
between changes in concentrations of HDL-cholesterol and changes in BMIs, 
concentrations of 17β-estradiol, testosterone, IGF-I, and IGFBP-3 (III). To assess the 
relationship of BMD with hormonal factors and BMI, the changes in lumbar spine and 
femoral neck BMAD between 0 and 12 months were compared with the means of 
serum concentrations of 17β-estradiol, testosterone, DHT, IGF-I, IGFBP-3, and BMI at 
2, 5, and 12 months by Spearman’s correlation (IV). All statistical tests were two-sided. 
A p-value of less than 0.05 was considered statistically significant. 
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Table 2. Serum IGF-I and IGFBP-3 concentrations. 
_____________________________________________________________________________________ 
 No treatment Testosterone + Testosterone + p-value a 
  placebo letrozole 
_____________________________________________________________________________________ 
IGF-I (nmol/l) 
0 month 27.4 ± 3.8 28.3 ± 2.7 30.3 ± 3.4 
2 months 28.7 ± 2.9 34.0 ± 2.4b 25.6 ± 1.5  0.01 
5 months 25.9 ± 2.0 34.5 ± 2.3b 25.2 ± 1.6 0.01 
12 months 29.3 ± 3.3 34.3 ± 2.9b 27.4 ± 1.0 0.06 
18 months 27.9 ± 2.6 31.9 ± 2.6 34.1 ± 1.2 0.9 
IGFBP-3 (mg/l)  
0 month 3.7 ± 0.2 3.8 ± 0.1 3.7 ± 0.2  
2 months 3.7 ± 0.3 4.1 ± 0.2b 3.6 ± 0.2 0.02 
5 months 3.8 ± 0.2 4.3 ± 0.2c 3.4 ± 0.2 0.0004 
12 months 3.9 ± 0.2 4.3 ± 0.1d 3.5 ± 0.2 0.008 
18 months 4.5 ± 0.2b 4.7 ± 0.2c 4.4 ± 0.2c 0.8 
_____________________________________________________________________________________ 
Mean ± SEM. a p-value refers to the difference between treatment groups regarding changes in value from 
the start to the time point indicated by the p-value. b p<0.05, c p<0.001, d p<0.01 for change within each 
group from the start to the indicated time point. 
 
 
GROWTH (I) 
 
From the start to 5 months of treatment, the boys treated with testosterone and placebo 
grew slightly faster than those treated with testosterone and letrozole (9.9 ± 0.5 cm/year 
vs. 7.3 ± 0.9 cm/year, respectively, p=0.02; Table 3). After 5 months, no statistically 
significant differences in growth velocity were observed between the two treated 
groups, although a trend of higher growth velocity was observed in the testosterone-
plus-letrozole-treated than in the testosterone-plus-placebo-treated group after 
discontinuation of treatments (p=0.06; Table 3). No correlation was found between 
height velocity during the first 5 months and serum IGF-I, IGFBP-3, 17β-estradiol, 
testosterone, or DHT concentration at 5 months.    
 
 
BONE AGE (I) 
 
Inhibition of estrogen synthesis by letrozole delayed bone maturation. Within the 18-
month follow-up period, bone age increased 1.7 ± 0.3 years in the testosterone-plus-
placebo-treated group but only 0.9 ± 0.2 years in the testosterone-plus-letrozole-treated 
group (significance of the difference between treatment groups, p=0.03; Figure 7). In 
the untreated group, the respective increment was 1.1 ± 0.3 years (Figure 7). 
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difference between the treatment groups regarding the change in predicted adult height 
was significant (p=0.04).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Change in predicted adult height (mean ± SEM) from the start to 18 months. 
 
 
PROGRESSION OF PUBERTY (I) 
 
Puberty advanced in all groups during the follow-up. The Tanner stages of puberty 
progressed in a similar fashion in the two treatment groups (I). The increase in testis 
volume was greater during treatment with testosterone and letrozole than during 
treatment with testosterone and placebo, which is consistent with the differences in 
gonadotropin concentrations (Table 4). Gynecomastia was found in 2 boys in the 
testosterone-plus-placebo-treated group, in 2 boys in the testosterone-plus-letrozole-
treated group, and in none of the boys in the untreated group.  
 
 
BODY COMPOSITION (III, IV) 
 
In the testosterone-plus-placebo-treated group, BMI did not change during the follow-
up (III). In the testosterone-plus-letrozole-treated group, BMI was higher during 
letrozole treatment than at the start, but 6 months after discontinuation of letrozole 
treatment it did not differ from the pretreatment level (III).  
There were no differences between the two treated groups in increases of FFM. 
The decreases in FM and in the percentage of FM were more profound in the 
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testosterone-plus-placebo-treated than in the testosterone-plus-letrozole-treated group 
from the start to 5 months but similar at the other time points (III).  
 
 
Table 4. Testis volume and serum inhibin B concentration. 
_____________________________________________________________________________________ 
 No treatment Testosterone + Testosterone + p-value a 
  placebo letrozole 
_____________________________________________________________________________________ 
Testis volume (ml) b 
0 month 5.9 ± 0.9 6.9 ± 1.2 5.5 ± 0.6 
5 months 8.1 ± 1.4 8.9 ± 1.5 11.5 ± 1.6 0.01 
12 months 12.0 ± 1.8 13.4 ± 1.7 16.8 ± 1.2 0.0005 
18 months 14.7 ± 2.3 18.6 ± 2.0 19.1 ± 1.1 0.2 
Inhibin B (ng/l) 
0 month 153.7 ± 12.1 176.1 ± 12.5 161.2 ± 16.2  
5 months 186.4 ± 18.1 155.5 ± 21.8 200.5 ± 18.8 0.01 
12 months 184.6 ± 10.3c 186.6 ± 19.0 219.8 ± 15.9d 0.1 
18 months 180.6 ± 11.4d 216.8 ± 19.1 203.1 ± 16.6 0.8 
_____________________________________________________________________________________ 
Mean ± SEM. a p-value refers to the difference between treatment groups regarding changes in value from 
the start to the time point indicated by the p-value. b From the formula length x width2 x 0.52 (Hansen et 
al. 1952). c p<0.01, d p<0.05 for change within each group from the start to the indicated time point.  
 
 
 
BONE METABOLISM (I, IV) 
 
Bone mineral density (I, IV) 
 
Lumbar spine  
In both treatment groups, BMC and bone area increased during the treatments (Figure 
9). An increase was also observed in BMD and BMAD in both treated groups during 
the follow-up, although in the testosterone-plus-letrozole-treated group, the increase in 
BMAD was statistically significant only at 18 months, i.e. 6 months after 
discontinuation of letrozole treatment (Figure 9). When the changes from the start in 
BMC, bone area, BMD, and BMAD were compared between the treated groups, no 
statistically significant differences were observed at any time point.  
To study the association of BMAD with hormonal factors and BMI, the changes 
in BMAD between 0 and 12 months were compared with the means of 17β-estradiol, 
testosterone, DHT, IGF-I, IGFBP-3, and BMI at 2, 5, and 12 months in a group 
including all boys. The changes in lumbar spine BMAD correlated with 17β-estradiol 
(correlation coefficient (r) =0.5, p=0.009) and IGF-I (r=0.5, p=0.01) concentrations, but 
no significant associations with other variables were observed.  
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Femoral neck 
BMC and bone area increased during treatment in both treated groups (Figure 9). BMD 
increased in the testosterone-plus-placebo-treated group, but in the testosterone-plus-
letrozole-treated group, no change was observed (Figure 9). BMAD did not change 
significantly in any of the groups, except for a decrease in the testosterone-plus-
placebo-treated group from the start to 5 months (Figure 9). However, a decreasing 
trend in BMAD in all groups was observed (Figure 9). When the changes from the start 
in BMC, bone area, BMD, and BMAD were compared between the treated groups, no 
differences were observed.  
The correlations between changes in femoral neck BMAD between 0 and 12 
months and the means of 17β-estradiol, testosterone, DHT, IGF-I, IGFBP-3, and BMI at 
2, 5, and 12 months were determined in a group including all boys. The only significant 
association was observed between changes in femoral neck BMAD and IGFBP-3 
concentration (r=0.4, p=0.02).  
 
 
Bone turnover (IV) 
 
During treatment with testosterone and placebo a simultaneous increase occurred in 
both bone resorption and formation markers (Figure 10). During treatment with 
testosterone and letrozole the concentrations of CTx, PICP, and OC remained 
unchanged, whereas an increase was seen in the concentrations of ICTP and ALP 
(Figure 10). The untreated group showed a similar pattern of changes; i.e., no change in 
the concentrations of CTx, PICP, and OC but an increase in ICTP and ALP 
concentrations. 
 
 
LIPIDS (III) 
 
The HDL-cholesterol concentration decreased more during the treatment with 
testosterone and letrozole than during the treatment with testosterone and placebo 
(Table 5). In the testosterone-plus-placebo-treated group, no significant change in the 
HDL-cholesterol concentration was observed during the follow-up; the concentration 
was 1.56 ± 0.09 mmol/l at the start, and the lowest value of 1.40 ± 0.12 mmol/l was 
observed at 18 months (p=0.2; Table 5). In the testosterone-plus-letrozole-treated group, 
the concentration decreased from 1.62 ± 0.12 mmol/l at the start to the lowest level of 
1.20 ± 0.09 mmol/l at 5 months (p=0.002), but no subsequent decrease was observed 
(1.34 ± 0.09 mmol/l at 18 months; Table 5). In the untreated group, the concentration 
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INSULIN (III) 
 
In the testosterone-plus-placebo-treated group, the fasting insulin concentration 
remained unchanged (Table 5). By contrast, in the testosterone-plus-letrozole-treated 
group, the fasting insulin concentration decreased during letrozole treatment (p=0.04, 
from the start to 12 months), and after discontinuation of letrozole treatment, increased 
to the pretreatment level (Table 5). The changes in fasting insulin concentration from 
the start to 12 months in the two treatment groups were different (p=0.02).  
To investigate the relationship between fasting insulin concentrations and BMIs, 
sex steroids, and growth factors, the changes from the start in fasting insulin 
concentrations were compared with the changes in BMIs, concentrations of 17β-
estradiol, testosterone, IGF-I, and IGFBP-3; the data for the boys in the two treatment 
groups are combined. The changes in serum insulin and IGF-I concentrations from the 
start to 12 months and 18 months were correlated (r=0.5, p=0.04 for both). No 
associations between other variables were observed.  
 
 
Table 5. Serum concentrations of HDL-cholesterol, LDL-cholesterol, triglycerides, and 
insulin. 
_____________________________________________________________________________________ 
 No treatment Testosterone + Testosterone + p-value a 
  placebo letrozole 
_____________________________________________________________________________________ 
HDL-cholesterol (mmol/l) 
0 month 1.8 ± 0.1 1.6 ± 0.1 1.6 ± 0.1  
5 months 1.6 ± 0.1 1.5 ± 0.1 1.2 ± 0.1b 0.005 
12 months 1.5 ± 0.1 1.6 ± 0.1 1.4 ± 0.1c 0.06 
18 months 1.4 ± 0.1d 1.4 ± 0.1 1.3 ± 0.1c 0.3 
LDL-cholesterol (mmol/l) 
0 month 2.2 ± 0.2 2.4 ± 0.2 2.5 ± 0.2  
5 months 2.7 ± 0.2 2.4 ± 0.2 2.5 ± 0.2 0.5 
12 months 2.5 ± 0.2 2.4 ± 0.2 2.6 ± 0.2 0.4 
18 months 2.3 ± 0.2 2.4 ± 0.2 2.3 ±0.2 0.9 
Triglycerides (mmol/l) 
0 month 0.58 ± 0.06 0.91 ± 0.12 0.89 ± 0.15  
5 months 0.62 ± 0.08 0.86 ± 0.12 0.96 ± 0.14 0.6 
12 months 0.70 ± 0.17 0.89 ± 0.15 0.85 ± 0.11 0.6 
18 months 0.69 ± 0.11 0.85 ± 0.10 1.13 ± 0.18 0.3 
Insulin (mU/l) 
0 month 5.7 ± 0.8 7.1 ± 0.7 9.2 ± 1.3  
5 months 6.2 ± 1.2 6.8 ± 0.7 6.2 ± 0.9 0.2 
12 months 6.6 ± 1.4 9.1 ± 1.2 6.5 ± 0.8d 0.02 
18 months 7.6 ± 1.7 8.8 ± 1.2 9.4 ± 1.3 0.3 
_____________________________________________________________________________________ 
Mean ± SEM. a p-value refers to the difference between treatment groups regarding changes in value from 
the start to the time point indicated by the p-value. b p<0.01, c p<0.02, d p<0.05 for change within each 
group from the start to the indicated time point. 
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Figure 12. Serum basal (□) and GnRH-induced peak (■) LH and FSH concentrations 
(mean + SEM) at the start and at 5 months. Boys in the no group did not receive any 
treatment, boys in the t + pl group received testosterone and placebo, and boys in the t + 
lz group received testosterone and letrozole. Asterisks denote significant changes from 
the start within each group: *, p<0.05; **, p<0.01; ***, p<0.001.  
 
 
 
Spontaneous gonadotropin pulses (II) 
 
The gonadotropin pulses of a representative boy of both treatment groups are shown in 
Figure 13. Before treatment, nocturnal elevation in gonadotropin concentrations, 
characteristic of early and midpubertal boys, was seen in all of the boys. During 
treatment with testosterone and placebo the nocturnal LH concentrations were lower 
than at the start of treatment in 4 of the 5 boys, and the FSH concentrations in all of the 
boys. In 3 of the boys in the testosterone-plus-placebo-treated group, the LH 
concentrations decreased to or below the detection limit, and therefore, no pulses could 
be determined, but in the other 2 boys, gonadotropin pulses and nocturnal increases in 
concentrations were observed during treatment. Since pulses could be observed in only 
2 of the 5 boys during treatment with testosterone and placebo, the changes in the pulse 
variables were not calculated.  
In the testosterone-plus-letrozole-treated group, the nocturnal LH and FSH 
concentrations increased in all of the boys during treatment; gonadotropin pulses and 
the diurnal profile of gonadotropin secretion were also observed. In the testosterone-
plus-letrozole-treated group, the mean LH pulse amplitude, calculated from all of the 
LH pulse amplitudes detected, increased during treatment (p=0.01); no significant 
changes were seen in FSH pulse amplitude, gonadotropin pulse frequencies, or 
interpulse intervals.  
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DISCUSSION 
 
 
This study was undertaken to evaluate whether suppression of estrogen synthesis by the 
P450 aromatase inhibitor letrozole in boys with delayed puberty delays maturation of 
the growth plates, ultimately resulting in increased adult height. The rationale for giving 
the boys this new P450-aromatase inhibitor was the hypothesis that this treatment would 
help them to achieve their genetic height potential.  
At the start of follow-up, the mean testosterone concentrations were 
approximately 10 nmol/l, suggesting that some boys were already at early or 
midpuberty. However, because blood samples were drawn only between 07:30 and 
10:15, these levels do not reflect the mean diurnal testosterone concentrations, which 
are much lower (Boyar et al. 1974; Parker et al. 1975). Testosterone secretion in boys 
during puberty has a clear diurnal rhythm, with a peak early in the morning and 
significantly lower concentrations in the afternoon and evening (Boyar et al. 1974; 
Parker et al. 1975). In some boys, puberty might have advanced spontaneously in a short 
time without any treatment. However, treating these boys was justified since none had 
had a pubertal increase in growth velocity prior to treatment and all of those treated 
desired medical intervention.  
 
 
LETROZOLE IN PUBERTAL BOYS 
 
An aromatase inhibitor was used in this study for the first time in the treatment of boys 
with delayed puberty. This was also the first time that a potent, fourth-generation 
aromatase inhibitor was used in early and midpubertal adolescents. 
 
Efficacy in inhibiting estrogen synthesis 
 
Letrozole at a dose of 2.5 mg/day was found to be an effective inhibitor of estrogen 
synthesis in pubertal boys, consistent with previous reports in adult males (Trunet et al. 
1993). Exogenous letrozole inhibited both the increase in 17β-estradiol concentrations 
associated with testosterone administration and the increase in endogenous 17β-
estradiol concentrations during spontaneous progression of puberty.  
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Tolerability and safety 
 
Letrozole was well tolerated. During the one-year treatment with this P450 aromatase 
inhibitor no side-effects indicating discontinuation of treatment were observed. 
However, some disadvantageous effects on BMD and HDL-cholesterol may occur. For 
this reason, it is important to follow up bone metabolism, BMD, and lipid 
concentrations during treatment with P450 aromatase inhibitors.  
Estradiol has been shown to act as a germ cell survival factor in the human testis 
in vitro (Pentikäinen et al. 2000). The role of estrogen in the regulation of human 
spermatogenesis in vivo can be assessed by the findings in men with a mutation in the 
gene for ERα (Smith et al. 1994) or in the P450 aromatase enzyme (Carani et al. 1997). 
The man with a mutation in the ERα gene had a testis volume of 20-25 ml and a normal 
sperm density (25 x 106 / ml) but a decreased sperm viability of 18% (normal >50%) 
(Smith et al. 1994). The aromatase-deficient male had a subnormal testis volume (8 ml) 
and a decreased sperm count (≤1 x 106 / ml; normal >20 x 106 / ml) with 100% immotile 
spermatozoa (Carani et al. 1997). However, abnormal findings in semen analysis of the 
aromatase-deficient subject may be unrelated to suppression of estrogen action since 
azoospermia and infertility were also reported in the subject’s brother, who had a 
normal P450 aromatase gene (Carani et al. 1997). Moreover, the results of semen 
analysis did not change during treatment with transdermal estradiol (Carani et al. 1997), 
suggesting nonestrogen-dependent spermatogenic damage. Neither treatment with 
testosterone and letrozole nor treatment with testosterone alone had an adverse effect on 
testis size or inhibin B concentration. These findings suggest that a one-year treatment 
with P450 aromatase inhibitors in early and midpubertal boys does not adversely affect 
spermatogenesis. Sperm analysis will ultimately confirm this issue.  
 
 
EFFECT OF P450 AROMATASE INHIBITION 
 
Growth 
 
The boys treated with testosterone and letrozole grew at a slower rate during the first 5 
months of treatment than those treated with testosterone alone. This finding confirms 
testosterone accelerating growth via an estrogen-dependent mechanism. The growth-
enhancing effect of estrogens may result, at least partly, from stimulation of GH 
secretion by estrogens (Metzger et al. 1994). Consistent with this, IGF-I and IGFBP-3 
concentrations increased during treatment with testosterone alone but did not change 
during combined treatment with testosterone and letrozole. Our findings further suggest 
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that other factors, in addition to estrogens, are involved in pubertal growth acceleration 
in males since during letrozole treatment the majority of boys grew with normal 
pubertal growth velocity despite low 17β-estradiol concentrations. If aromatization of 
androgens is inhibited, steroid biosynthesis is directed to produce 5α-DHT, and 
subsequently, 3β-androstanediol. The latter is a weak estrogen that has been 
demonstrated to bind to estrogen receptors (Kuiper et al. 1997) and may therefore have 
estrogenic effects. Thus, the normal pubertal growth velocity during letrozole treatment 
could also have resulted from activation of ER. 
Consistent with the original hypothesis, inhibition of estrogen synthesis did delay 
bone maturation. It is noteworthy that in boys treated with both testosterone and 
letrozole bone maturation was slower, despite considerably higher androgen 
concentrations, than in those treated with testosterone alone. This finding confirms the 
view that estrogens are more important than androgens in bone maturation in pubertal 
males and agrees with observations on males who lack estrogen action (Smith et al. 
1994; Morishima et al. 1995; Carani et al. 1997). Furthermore, even after 
discontinuation of all treatments, the progression of bone maturation was slower in the 
boys treated with testosterone and letrozole than in those treated with testosterone alone, 
indicating that the effect of treatment outlasts the treatment period (Joss et al. 1989).  
Delayed bone maturation simultaneously with good growth response resulted in 
an increase in predicted adult height in boys treated with testosterone and letrozole. This 
supports the primary hypothesis that inhibition of estrogen synthesis in growing 
adolescents increases adult height. Since boys with CDP do not appear to fully exploit 
their genetic growth potential (Crowne et al. 1990; LaFranchi et al. 1991; Albanese et 
al. 1993, 1995), it is possible that these boys could achieve an adult height closer to 
their full potential if estrogen actions are inhibited. The observations that the predicted 
adult height did not change either in the boys who were treated with testosterone alone 
or in those who had received no treatment are consistent with previous studies, which 
have shown that androgen treatment does not increase adult height (Blethen et al. 1984; 
Martin et al. 1986; Albanese et al. 1993). When adult height predictions by the Bayley-
Pinneau method were calculated, the table for boys with average skeletal maturity had 
to be used as the bone ages in most of the boys exceeded the range of bone ages 
reported for boys with retarded skeletal maturity. One might speculate whether this had 
biased the results. Adult height prediction was, however, only a tool to illustrate 
whether aromatase inhibition delays bone maturation. This tool has limitations and 
biases, and whether one-year letrozole treatment in pubertal boys actually increases 
adult height will only be confirmed when these boys reach adulthood.   
The two treatments advanced the appearance of secondary sexual characteristics 
similarly, despite considerably higher androgen concentrations in the boys treated with 
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testosterone and letrozole. The reason why highly supraphysiological androgen 
concentrations did not advance puberty more rapidly is unclear. Possibly, the maximal 
effect at cell level is attained with a certain concentration of testosterone, and 
concentrations above this threshold level do not enhance the biological effect. Small 
differences in rates of progression of puberty between the two treatment groups may 
also have remained undetected due to the small number of patients in this study.     
 
 
Peak bone mass 
 
No significant differences were present in changes in BMC, BMD, or BMAD of lumbar 
spine or proximal femur between the groups treated with testosterone and letrozole and 
with testosterone alone. This suggests that one-year letrozole treatment in pubertal boys 
is unlikely to have any major harmful effect on BMD. This is supported by findings in 
bone turnover markers. They do not suggest a significant imbalance between bone 
resorption and formation during either of the treatments. The reports of males with an 
inactive ERα (Smith et al. 1994) or a defective aromatase enzyme (Morishima et al. 
1995; Carani et al. 1997) demonstrate that estrogen action is needed for optimal 
development of peak bone mass in males. Patients with androgen insensitivity 
syndrome also have decreased BMD even before the age when peak bone mass is 
achieved (Bertelloni et al. 1998b; Marcus et al. 2000), indicating that endogenous 
androgens are also essential in the development of peak bone mass. In the letrozole-
treated boys, high androgen concentrations may have to some extent compensated for 
possible harmful effects of low estrogens. However, one must recognize the limited 
power of a study of this size, particularly in detecting minor or rare side-effects. 
Confirmation of the safety of this treatment requires a larger study sample. It is 
noteworthy that no statistically significant increase occurred in femoral neck BMD or 
lumbar spine BMAD during suppression of estrogen action by letrozole, while these 
parameters showed an increase in the boys treated with testosterone alone who had 
intact P450 aromatase activity.  
Some evidence exists that estrogens are more important than androgens in the 
regulation of developing peak bone mass in males. The rate of increase in BMD of the 
arms of young men correlated positively with estrogen but not testosterone 
concentrations (Khosla et al. 2001). While a positive correlation between the changes in 
lumbar spine BMAD and 17β-estradiol was found, no association was present between 
the changes in BMAD and testosterone or DHT. If disadvantageous effects on bone 
mass accretion occur during letrozole treatment, they may be also due to lower activity 
of the GH-IGF-I axis. GH has a significant role in bone mass accretion during growth. 
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In children with GH deficiency, reduced BMD has been demonstrated to increase 
during GH treatment (Zamboni et al. 1991; Saggese et al. 1993; Boot et al. 1997; 
Baroncelli et al. 1998). During letrozole treatment IGF-I and IGFBP-3 concentrations 
remained unchanged, while during treatment with testosterone and placebo both 
concentrations increased. Moreover, changes in lumbar spine BMAD correlated 
positively with IGF-I concentrations, and changes in femoral neck BMAD with IGFBP-
3 concentrations. Since estrogens have a very important role in the regulation of BMD 
directly or indirectly through the GH-IGF-I axis (Metzger et al. 1994), it is essential to 
follow up BMD regularly during treatment with P450 aromatase inhibitors. 
Although the areal BMD in the femoral neck increased in the boys treated with 
testosterone alone, the BMAD, an estimate of volumetric BMD, decreased within the 
first 5 months, which was unexpected. This may have resulted from an inaccuracy in 
estimated BMAD since the model for calculating BMAD had not been validated by a 
direct measurement of the volume of the femoral neck (Katzman et al. 1991). However, 
the decreasing trend in the femoral neck BMAD did not reach statistical significance at 
12 or 18 months in any of the groups, which is in accord with previous findings of 
unchanged values of femoral neck BMAD in boys with increasing age (Kröger et al. 
1992; Faulkner et al. 1996).  
It is unclear whether the timing of puberty is a significant determinant of peak 
BMD in men. Men with a history of CDP have been shown to have osteopenia in 
adulthood (Finkelstein et al. 1992, 1996, 1999). On the other hand, normal volumetric 
BMD has also been reported in these men (Bertelloni et al. 1998a). Reasons for the 
discrepancy between these studies remain uncertain, although they may be related to 
most of the men in the latter study receiving androgen therapy to induce puberty 
(Bertelloni et al. 1998a). However, the possibility that a history of delayed puberty may 
be associated with osteopenia in adult life further highlights the importance of a close 
follow-up of developing bone mass during treatment with P450 aromatase inhibitors in 
boys with delayed puberty.  
 
 
Serum lipid concentrations 
 
HDL-cholesterol concentration decreased in the boys treated with testosterone and 
letrozole, but did not change in those treated with testosterone alone. This suggests that 
letrozole may have disadvantageous effects on HDL-cholesterol metabolism. The 
finding agrees with observations on aromatase-deficient males whose subnormal HDL-
cholesterol concentrations increased during estrogen administration (Morishima et al. 
1995; Carani et al. 1997; Bilezikian et al. 1998). In the letrozole-treated group, the 
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lowest level in HDL-cholesterol concentration was observed at 5 months, and no 
decrease was found thereafter despite letrozole treatment continuing. Moreover, the 
HDL-cholesterol concentration in the letrozole-treated boys was similar to levels in the 
boys of the other two groups 6 months after discontinuation of all treatments. Thus, 
letrozole treatment for one year in pubertal boys is unlikely to have a permanent 
harmful effect on HDL-cholesterol. However, the findings emphasize the importance of 
regular follow-up of HDL-cholesterol during administration of P450 aromatase 
inhibitors. 
The more profound decrease in HDL-cholesterol concentration in the group 
treated with testosterone and letrozole than in the group treated with testosterone alone 
may be due to the greater increase in androgen concentrations with the former 
treatment. This is supported by the finding that decreasing HDL-cholesterol 
concentrations correlated with increasing testosterone concentrations. Previous studies 
have also suggested that androgens regulate HDL-cholesterol in boys during puberty 
(Kirkland et al. 1987; Arslanian et al. 1997; Morrison et al. 1998, 2000; Saad et al. 
2001). On the other hand, the decrease in HDL-cholesterol concentration in the boys 
treated with testosterone and letrozole may in part have resulted from the inhibition of 
estrogen action. Estrogens suppress the activity of hepatic lipase (Applebaum et al. 
1977) which catalyzes the degradation of HDL2 lipids. However, no correlation was 
found between changes in HDL-cholesterol concentrations and changes in 17β-estradiol 
concentrations in this study. Neither was there any association between estradiol and 
HDL-cholesterol concentrations in earlier studies of adolescent boys (Morrison et al. 
1998, 2000). Thus, estrogens may have a less important role than androgens in the 
regulation of HDL-cholesterol in boys during early and midpuberty. The difference in 
changes in HDL-cholesterol in the two treated groups may also partly have been due to 
differences in changes in BMIs. BMI increased concomitantly with decreasing 
concentrations of HDL-cholesterol during the treatment with testosterone and letrozole, 
but neither BMI nor HDL-cholesterol changed in the group treated with testosterone 
alone. Moreover, decreasing HDL-cholesterol concentrations correlated with increasing 
BMI. The previous findings of an inverse relationship between HDL-cholesterol 
concentration and BMI in adolescent boys (Morrison et al. 1998, 2000) supports the 
importance of body composition in the regulation of HDL-cholesterol concentration.  
The concentrations of LDL-cholesterol and triglycerides did not change during 
either of the treatments, suggesting that treatment with a P450 aromatase inhibitor does 
not contribute significantly to the regulation of concentrations of LDL-cholesterol or 
triglycerides in early and midpubertal boys. It is noteworthy that no changes occurred in 
concentrations of LDL-cholesterol and triglycerides in either treatment group despite 
great differences in sex steroid concentrations. This suggests that sex steroids do not 
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have important roles in the regulation of LDL-cholesterol and triglycerides in boys at 
this stage of puberty. However, previous studies have reported that changes in 
lipoprotein concentrations in adolescent boys can be explained, to some extent, by 
changes in body mass, in testosterone and estrogen levels, and their interactions 
(Laskarzewski et al. 1983a, 1983b). Moreover, estrogens at physiological 
concentrations appear to have a favourable effect on LDL-cholesterol and triglycerides 
in adult males (Morishima et al. 1995; Carani et al. 1997; Bilezikian et al. 1998). For 
these reasons, follow-up of lipid profiles during administration of P450 aromatase 
inhibitors is recommended. 
 
 
Insulin sensitivity 
 
Decreasing insulin sensitivity during puberty simultaneously with the rise in 
concentrations of sex steroids is a well-known phenomenon (Amiel et al. 1986, 1991; 
Bloch et al. 1987; Caprio et al. 1989; Smith et al. 1989). The role of sex steroids in the 
development of puberty-associated insulin resistance is, however, unclear.  
P450 aromatase inhibition in early and midpubertal boys does not appear to have 
disadvantageous effects on insulin sensitivity. During letrozole treatment fasting insulin 
concentrations decreased, suggesting an improvement in insulin sensitivity despite 
higher increases in androgen concentrations than in the group treated with testosterone 
alone, in which fasting insulin concentrations remained unchanged. This finding implies 
that an increase in the concentration of androgens during puberty does not directly 
contribute to the development of puberty-associated insulin resistance in boys, agreeing 
with the results of other studies (Arslanian et al. 1997; Saad et al. 2001). Neither do 
estrogens appear to have a direct role in the regulation of insulin sensitivity in boys 
during puberty. The changes in 17β-estradiol concentrations did not correlate with 
changes in fasting insulin concentrations. The changes in insulin sensitivity in boys 
during progression of puberty also showed no association with changes in estradiol 
concentrations in another study (Goran et al. 2001). Decreasing insulin sensitivity has 
been demonstrated to be associated with increasing BMI in adolescent boys (Cook et al. 
1993). The decrease in the fasting insulin concentration during letrozole treatment was 
obviously not a consequence of decreased body mass since BMI increased during 
treatment. The decrease may have been due to the suppression of GH secretion, as no 
pubertal increases in IGF-I or IGFBP-3 concentrations were observed during letrozole 
treatment. This assumption is supported by the finding that changes in fasting insulin 
concentrations correlated positively with changes in IGF-I concentrations. These 
observations are in accord with a decrease in insulin sensitivity during puberty resulting 
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from the increasing action of GH (Amiel et al. 1986; Bloch et al. 1987; Caprio et al. 
1989; Smith et al. 1989; Heptulla et al. 1997; Moran et al. 2002). Since androgens can 
be converted to estrogens which are able to augment GH secretion (Metzger et al. 
1994), the effects of GH on regulation of insulin sensitivity may also indirectly reflect 
the action of sex steroids.  
Fasting insulin concentration, which was used as an index of insulin resistance, 
has been demonstrated to correlate well with insulin resistance measured by the 
euglycemic insulin clamp technique (Olefsky et al. 1973). While measuring only a 
single fasting insulin concentration is not optimal for assessing insulin sensitivity, more 
accurate methods, such as the euglycemic insulin clamp techinique, would have made 
the study protocol too demanding for the boys. Differences in fasting insulin 
concentrations between the two treated groups could theoretically be explained by 
differences in blood glucose concentrations, but this is considered unlikely since 
letrozole has not been shown to affect fasting blood glucose (Berstein et al. 2002). 
However, absence of fasting blood glucose concentrations impedes interpretation of 
results. Further studies with more appropriate methods are needed to confirm whether 
P450 aromatase inhibitor treatment has an impact on insulin sensitivity. 
  
 
ROLE OF SEX STEROIDS IN GONADOTROPIN SECRETION 
IN PUBERTAL BOYS 
 
Endogenous androgens appear to inhibit gonadotropin secretion in boys from the early 
stages of puberty onwards (Santen et al. 1976). Supraphysiological estradiol 
concentrations, attained by estradiol infusion, decreased LH concentrations in early and 
midpubertal boys (Kletter et al. 1997), which suggests the existence of negative 
feedback between estrogen and gonadotropin secretion. This study showed that when 
the action of low concentrations of endogenous estrogens was suppressed by letrozole, 
LH and FSH concentrations increased despite very high androgen concentrations. This 
indicates that the negative feedback between endogenous estrogens and gonadotropin 
secretion, established in adult men (Smith et al. 1994; Morishima et al. 1995; Carani et 
al. 1997; Bilezikian et al. 1998; Hayes et al. 2000), is operative from early puberty 
onwards. Furthermore, the observations suggest that androgens have a less important 
role than estrogens in the regulation of LH and FSH secretion in early and midpubertal 
boys. 
When the action of endogenous estrogens was suppressed by the treatment with 
testosterone and letrozole, the LH pulse amplitude and the GnRH-induced LH response 
increased, but the LH pulse frequency, which is assumed to reflect the frequency of 
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hypothalamic GnRH secretion (Clarke et al. 1982; Levine et al. 1982), was unaffected. 
These observations suggest that low concentrations of endogenous estrogens in early 
and midpubertal boys may not influence the GnRH pulse generator, and that, in boys 
during early and midpuberty, the site of action of estrogens is the pituitary. Previous 
findings have, however, been contradictory. In early and midpubertal boys, estradiol 
infusion decreased LH concentrations and the LH pulse frequency but had no effect on 
the GnRH-induced LH response or the LH pulse amplitude (Kletter et al. 1997), 
suggesting a hypothalamic site of action for estrogens. The reason for this discrepancy 
is unclear. One possibility is that supraphysiological concentrations of estrogens and 
endogenous estrogens act on gonadotropin secretion differently. In the previous study, 
supraphysiologic estradiol concentrations were attained by exogenous administration 
(Kletter et al. 1997). By contrast, in the group treated with testosterone plus letrozole in 
this study, the effects of suppression of low, early pubertal concentrations of estrogens 
were demonstrated. The evaluation of the precise sites of the negative feedback of 
gonadal steroids in the hypophyseal-pituitary unit is difficult in vivo. In humans, 
monitoring hypothalamic GnRH secretion directly is not possible since GnRH is 
consumed in the hypophyseal-portal blood due to its short half-life of 2-4 minutes 
(Hayes et al. 1998). In animal models, an exact temporal relationship between GnRH 
secretion and LH secretion has been observed (Clarke et al. 1982; Levine et al. 1982), 
and thus, monitoring LH pulse frequency in humans has been used in estimating the 
frequency of hypothalamic GnRH secretion. The results of indirect methods may not, 
however, demonstrate the true site of action at the hypothalamic-pituitary unit. This, as 
well as different pulse detection programs which were used, may also partly explain the 
discrepancy between this and the previous study (Kletter et al. 1997). Thus, future 
studies with larger patient groups and longer periods of blood sampling are needed to 
confirm the conclusions drawn here regarding the pituitary site of action of endogenous 
estrogens and to clarify whether endogenous estrogens also act at the hypothalamus in 
boys during early and midpuberty.  
The negative feedback regulation between FSH and endogenous estrogens has 
previously been observed in adult males (Trunet et al. 1993; Hayes et al. 2000). The 
results of this study suggest that this regulatory loop is already operative in early and 
midpubertal boys. Although inhibin B participates in the regulation of FSH secretion 
from early to midpuberty onwards (Nachtigall et al. 1996; Andersson et al. 1997; Byrd 
et al. 1998; Raivio et al. 2000; Hayes et al. 2001), the increase in FSH concentrations 
during letrozole treatment was probably not due to a diminished negative feedback 
signal from inhibin B, for inhibin B concentrations increased concomitantly with FSH 
concentrations.  
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The nocturnal augmentation of gonadotropin secretion, which is characteristic of 
early and midpubertal boys (Boyar et al. 1972; Beck et al. 1980), was demonstrated 
before the start of treatments in all of the boys and also in all boys during the 
testosterone plus letrozole treatment. Thus, the suppression of estrogen action does not 
affect the diurnal profile of gonadotropin secretion, nor does the considerable increase 
in the concentrations of androgens. This observation is in accord with previous findings 
of a diurnal rhythm in gonadotropin secretion in children with gonadal dysgenesis 
(Boyar et al. 1973; Ross et al. 1983) and indicates that the circadian rhythm of 
gonadotropin secretion is regulated by mechanisms mediated by the central nervous 
system.  
 
 
FUTURE PROSPECTS 
 
These results suggest that an increase in adult height can be attained in growing 
adolescent boys by inhibition of estrogen action. However, at the time of completion of 
this study, the skeleton was relatively immature and growth was not decelerating in 
most of the boys. Therefore, it is important to confirm whether a one-year P450 
aromatase inhibitor treatment actually increases adult height by following up the boys 
until attainment of final adult heights. Although our findings suggest that treatment for 
one year with letrozole in pubertal boys is unlikely to have any major harmful effects on 
developing peak bone mass, only by measuring BMD after the attainment of peak bone 
mass can firm conclusions be drawn. Moreover, while the treatment had no adverse 
effects on testis size or inhibin B concentration, suggesting that it did not adversely 
affect maturing spermatogenesis, sperm analysis is needed to ultimately confirm this 
issue. 
Since the results showed that bone maturation can be delayed by suppressing the 
action of estrogens in growing adolescents, fourth-generation P450 aromatase inhibitors 
may prove to be an efficient treatment in various growth disorders. Future studies are 
required to establish whether treatment with aromatase inhibitors can be used, for 
instance, in patients with precocious puberty or congenital adrenal hyperplasia with 
significantly advanced bone age, or in healthy boys with genetic short stature.  
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SUMMARY AND CONCLUSIONS  
 
 
This prospective, randomized, placebo-controlled study was undertaken to evaluate 
whether suppression of estrogen synthesis in boys with delayed puberty delays bone 
maturation and ultimately results in increased adult height. Since some boys with CDP 
do not exploit their full genetic growth potential, we hypothesized that these boys would 
achieve an adult height closer to their genetic growth potential if estrogen actions were 
inhibited.  
A total of 33 boys with CDP participated. Ten boys, who decided to wait for 
spontaneous progression of puberty without medical intervention, composed the 
untreated group. Twenty-three boys desired medical intervention and were randomized 
to receive one of two treatments: 12 boys received testosterone and placebo, and 11 
boys testosterone and a specific and potent P450 aromatase inhibitor, letrozole, for 
suppression of estrogen synthesis.  
 
The main conclusions of this study are: 
 
1. Letrozole was well tolerated and effectively inhibited estrogen synthesis in adolescent 
boys. Estradiol concentrations remained at pretreatment level during the administration 
of letrozole, whereas the concentrations increased during treatment with testosterone 
alone and during spontaneous progression of puberty.  
 
2. Letrozole treatment delayed bone maturation. During the 18-month follow-up bone 
age advanced 0.9 year in the group treated with testosterone and letrozole and 1.7 years 
in the group treated with testosterone alone. An increase of 5.1 cm in predicted adult 
height was seen in the boys who had received testosterone and letrozole, but no change 
was seen in those receiving testosterone alone or in the untreated boys. This finding 
suggests that an increase in adult height can be attained in growing adolescent boys by 
inhibiting estrogen action, allowing the boys with CDP to achieve an adult height closer 
to their genetic growth potential.   
 
3. No significant differences in changes in BMC, BMD, or BMAD, an estimate of true 
volumetric BMD, were observed between the two treated groups. Nor were there any 
significant imbalances between bone resorption and formation in either of these groups. 
These findings suggest that a one-year letrozole treatment in pubertal boys is unlikely to 
have any major harmful effects on BMD. However, although lumbar spine BMAD 
increased in both treated groups, in the group treated with testosterone and letrozole, the 
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increase was statistically significant for only 6 months after discontinuation of letrozole 
treatment. Thus, close follow-up of BMD during treatment with P450 aromatase 
inhibitors is warranted.  
 
4. HDL-cholesterol concentration decreased in the boys who had received testosterone 
and letrozole, whereas no change was observed in those receiving testosterone alone. 
However, the HDL-cholesterol concentrations were similar in all groups 6 months after 
the discontinuation of treatments. No changes in the concentrations of LDL-cholesterol 
or triglycerides were observed in any of the groups. Because treatment with P450 
aromatase inhibitors may have disadvantageous effects on HDL-cholesterol 
metabolism, a follow-up of lipid profile is important. 
 
5. Fasting insulin concentrations decreased during letrozole treatment, but no change 
was observed during treatment with testosterone alone, suggesting that treatment with 
P450 aromatase inhibitors in early and midpubertal boys has no disadvantageous effects 
on insulin sensitivity. Insulin concentration remaining unchanged in the boys treated 
with testosterone alone but decreasing during letrozole treatment despite a higher 
increase in androgen concentrations suggests that rising androgen concentrations during 
puberty do not directly contribute to the development of puberty-associated insulin 
resistance in boys. 
 
6. During the treatment with testosterone alone and simultaneously with increases in 
testosterone and 17β-estradiol concentrations basal LH and FSH concentrations 
decreased, but GnRH-stimulated gonadotropin responses remained unchanged. During 
the treatment with testosterone and letrozole, concomitantly with a higher increase in 
testosterone concentration and unchanged concentrations of 17β-estradiol, an increase 
occurred in basal gonadotropin concentrations, GnRH-induced LH response, and LH 
pulse amplitude. These findings demonstrate that low physiological concentrations of 
endogenous estrogens inhibit LH and FSH secretion in boys during early and 
midpuberty. The results also suggest that androgens have a less important role than 
estrogens in the regulation of gonadotropin secretion in these boys. Moreover, during 
this stage of puberty the endogenous estrogen-mediated regulation of LH secretion 
apparently occurs at the site of the pituitary.  
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